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NEW INSIGHTS INTO MOLECULAR MECHANISM OF
FLUDARABINE
ALINA D. BULGAR
ABSTRACT

Nucleotide analogs (e.g. fludarabine) are antimetabolites used in the treatment of
a wide variety of hematological malignancies and solid tumors. Upon being metabolized
to their active triphosphate form, these agents are incorporated into DNA. Among other
molecular targets, their incorporation may lead to activation of base excision repair
(BER) pathway. The molecular mechanism of BER recognition and repair of the
incorporated fludarabine has not yet been elucidated. The main focus of this research was
to study the involvement of BER pathway in the response to fludarabine induced DNA
damage. Also, the possibility of enhancing antineoplastic activity of fludarabine by
inhibition of BER (e.g. methoxyamine) was investigated.
Firstly, capacity of uracil DNA glycosylase to recognize and excise incorporated
fludarabine was established. Secondly, the formation of abasic (AP) sites after
fludarabine treatment was confirmed in different human cancer cell lines. These results
demonstrated that incorporated fludarabine, acting as an abnormal base in DNA, initiates
BER.
The possibility to enhance fludarabine-induced damage by inhibiting BER was
then considered. Exposure of cells to fludarabine and methoxyamine (MX) combined
regimens caused increased apoptosis, clonogenic death, upregulation of some key BER
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proteins, enhanced DNA strand breaks. It also enhanced anti-tumor effects in human
xenografts. This response of cells to fludarabine plus MX was due to MX binding to the
ara-AP sites formed by fludarabine, thus turning the repairable DNA damage into lethal
lesions. In addition, mitochondrial DNA was found to be targeted by fludarabine and
fludarabine plus MX. Apoptotic signaling from nuclear and mitochondrial DNA damage
triggered mitochondrial mediated cell death during BER disruption by MX.
The modulation of fludarabine cytotoxicity by manipulating BER via MX was
analyzed in a similar series of experiments using primary lymphocytes obtained from
CLL patients. MX enhancement of activity of fludarabine was confirmed; the results
showed that CLL cells were significantly more sensitive to the fludarabine in combination
with MX as assayed by cytotoxicity, apoptosis, and levels of DNA damage.
Collectively, these results show that the combination of fludarabine plus MX
represents a potential new clinical targeted therapy.
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CHAPTER I
INTRODUCTION: FLUDARABINE, BASE EXCISION REPAIR AND
CELL DEATH MECHANISMS OVERVIEW

1.1.

Fludarabine
1.1.1. Structure and development
The need of new therapeutic strategies in the treatment of leukemia and

lymphoma led to development of the active agent, cytarabine (ara-C) and set the stage for
development of other nucleoside analogues. Vidarabine (ara-A), an adenosine analog,
was proven clinically ineffective due to rapid metabolic clearance by adenosine
deaminase. This rapid inactivation of vidarabine by deamination suggested the need for
structural modifications that will confer resistance to deamination while maintaining the
antineoplastic potential. The addition of a fluorine substitute at the position 2 of adenine
nucleoside renders resistance to deaminase. Montgomery and Hewson were the first ones
to synthesize 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) [1-3]. Because F-ara-A
was relatively insoluble, its 5’-monophosphate (Fludarabine, Berlex Laboratories,
Richmond, CA) had been used in clinical settings (Figure 1-1).
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Figure 1-1.
Structures of Adenosine, Ara-adenosine and Fludarabine
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The monophosphate formulation of fludarabine is rapidly and quantitative
dephosphorylated to the nucleoside F-ara-A. This first pass metabolism is attributed to
5’-nucleosidase activities of erythrocytes and endothelial cells (Figure 1-2) [4]. F-ara-A is
actively taken into cells by nucleoside transport systems (hENT, hCNT) [5]. Inside the
cells, F-ara-A is rephosphorylated to monophosphate and subsequently to the diphosphate
and triphosphate (Figure 1-2). It has been shown that deoxycytidine kinase is the major
kinase for phosphorylation to the monophosphate [6], while adenylate kinase and
nucleoside diphosphate kinase are the enzymes responsible for the subsequent
phosphorylation steps. The triphosphate, F-ara-ATP is the main metabolite of fludarabine
and the only known to have cytotoxic activity.
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Figure 1-2
Transport and metabolism of Fludarabine

5

Blood vessel
2-F-ara AMP

Phosphatases

2-F-ara A

Carrier mediated uptake
(hENT, hCNT)
Cell membrane
2F-ara A

Deoxycytidine kinase

2F-ara AMP
Adenylate
kinase
2F-ara AMP
Nucleoside diphosphate
kinase
2F-ara ATP

6

1.1.2. Mechanisms of action
1.1.2.1.

Target: DNA polymerase

The principal pharmacodynamic effect of fludarabine is inhibition of DNA
synthesis, by targeting multiple enzymes at different steps in this process. The central
component of the DNA synthesis machinery is the DNA polymerase. Early reports
demonstrate that DNA polymerases are targets for the action of F-ara-ATP. F-ara-ATP
does not directly inhibit the enzymes, but its inhibitory properties are achieved after
incorporation into DNA [7]. The presence of a thymidylate in the template strand leads to
incorporation of F-ara-ATP competitively with dATP. When one F-ara-A was
incorporated into DNA strand , the DNA polymerases are inhibited or forced to pause at
that specific site in the DNA strand. This inhibitory property makes fludarabine a chain
terminator. Studies using cell-free systems have shown that significant percentage of Fara-AMP was at the terminal position in DNA extracted from cells incubated with [3H]Fara-A [8]. Human DNA polymerase α, β, γ and ε are the main polymerases that are
sensitive to inhibition by F-ara-ATP [9,10].
In addition, the stability of F-ara-AMP at the 3’ end suggests that it is resistant to
the proof-reading activities of DNA polymerases. DNA polymerase ε has been studied
for its associated 3’ to 5’ exonuclease activities. DNA polymerase ε has a 35 fold greater
affinity for F-ara-AMP-terminated DNA than for DNA terminated by deoxyadenosine
monophosphate. Removal of F-ara-AMP was slow and the excision of the subsequent
nucleotide was not observed. The velocity of the excision reactions was lower when
compared with the rate of deoxyadenosine monophosphate [11]. Thus, the polymerization
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and the proof reading activities associated with DNA polymerases are inhibited by the
presence of F-ara-A in the DNA strand.
1.1.2.2.

Target: Ribonucleotide reductase

Ribonucleotide reductase is the central and rate-limiting enzyme involved in the
synthesis of deoxyribonucleotides, the building blocks for DNA synthesis. Incubation of
cells with F-ara-A leads to reduction in cellular concentrations of deoxynucleotides and
DNA synthesis concomitant with increase in F-ara-ATP levels [12-14]. Fludarabine is an
allosteric inhibitor of ribonucleotide reductase resulting in reduction of the cellular
concentrations of deoxycytidine triphosphate (dCTP), deoxyadenosine triphosphate
(dATP) and deoxyguanosine triphosphate (dGTP) except for the concentrations of
deoxythymidine triphosphate (dTTP). Incubation of purified ribonucleotide reductase
with F-ara-ATP led to decreased enzymatic activity due to interaction with global
allosteric inhibitory site of the enzyme [7,9].
F-ara-ATP competes with dATP for incorporation into DNA strand, thus
reduction in dATP levels results in self-potentiation. Furthermore, fludarabine is also
involved in a different metabolic self-potentiation mechanism involving deoxycitidine
kinase. This enzyme is regulated by the levels of deoxynucleotides, mainly dCTP. Due to
decrease in the dCTP levels, the activity of deoxycytidine kinase is enhanced that will
result in increased phosphorylation rate of F-ara-A [15,16]. This is the rate limiting step
in accumulation of the cytotoxic metabolite, F-ara-ATP.
1.1.2.3.

Target: Inhibition of DNA primase

DNA replication is a fundamental process using different mechanism of synthesis
for each DNA strand, involving separate set of enzymes. Replication of the leading strand
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(5’ to 3’ direction) is a continuous process that uses either polymerase δ or ε. In contrast,
the replication of the lagging strand (3’ to 5’ direction) occurs discontinuously by the
sequential joining of the Okazaki fragments (200 nucleotides). Along the lagging strand's
template, DNA primase builds RNA primers in short bursts. DNA polymerases α are then
able to use the free 3' OH groups of the RNA primers to synthesize DNA in the 5'→3'
direction. Once the Okazaki fragments are completed, the RNA fragments are then
removed (different mechanisms are used in eukaryotes and prokaryotes). DNA ligase
then joins the deoxyribonucleotides together, completing the synthesis of the lagging
strand. It was previously reported that F-Ara-ATP inhibits the function of DNA primase.
More specifically, F-ara-ATP is a better substrate for this enzyme that the natural
substrate, adenosine triphosphate, leading to termination of RNA primer. Additonally,
DNA polymerase α is unable to add deoxynucleotides to the RNA primers terminated by
F-ara-AMP [17-19].
1.1.2.4.

Target: Inhibition of DNA ligase I

DNA ligase I has a role in both replication and repair of DNA. DNA ligase I seal
a single-stranded nick in a double-stranded DNA by catalyzing the formation of
phosphodiester bond between the 3’-hydroxyl of one piece of DNA with the 5’-phosphate
of an adjacent DNA. The enzymatic activity involves several steps. First, DNA ligase I
interacts with ATP to form a ligase-AMP complex with the release of pyrophosphate. In
the next step, nicked DNA interacts with the ligase-AMP complex to form a DNA-AMP
complex in which AMP is linked to the 5’-terminus of the nick. In the third step, a
phosphodiester bond is formed across the nick and AMP is released from the enzyme.
Fludarabine inhibits this process at two steps. Firstly, F-ara-ATP interacts directly with
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DNA ligase I to form a complex. This inhibition persisted even after removal of free Fara-ATP from treated enzyme. Secondly, the enzymatic activity of the DNA ligase I was
inhibited by the reaction with a DNA strand terminated in F-ara-AMP. The rate of the
ligation, using this substrate was 10 % of that of normal DNA. This data indicate that the
DNA strand with F-ara-AMP is a poor substrate for DNA ligase I [20].
1.1.2.5.

Inhibition of RNA synthesis

Fludarabine is been shown to incorporate not only in DNA, but also in RNA, as a
consequence is inhibitory to RNA synthesis. The inhibition of RNA synthesis is
dependent on concentration of F-ara-ATP [21]. RNA synthesis is enzymatically achieved
by RNA polymerase I, II and III. Incubation of human lymphoblast with fludarabine
resulted in incorporation of F-ara-A preferentially into poly (A+) RNA fraction. This
incorporation into RNA resulted in premature termination of RNA transcript and
subsequently impaired the protein synthesis.
1.1.3. Fludarabine in CLL: rationale for combination therapies
Fludarabine monotherapy is an established regimen for treatment of chronic
lymphocytic leukemia (CLL) achieving superior remission rate compared with older
treatment regimens containing alkylating agents or corticosteroid [22,23]. CLL is the
most common hematological malignancy in western world. CLL arises from a malignant
clone of B cells with a characteristic phenotype. The disease encompasses a diversity of
clinical symptoms which translate into variable prognosis and survival. Complete
response rates with fludarabine as single agents are 15-20 % in previously treated patients
and 40-50 % in newly diagnosed ones. However, this response rates are low and usually
transient, with all patients eventually experience a relapse [24,25]. Because fludarabine is
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not curative when used as monotherapy, efforts are made to improve fludarabine efficacy
by establishing a rational basis for combination with other drugs. Both biochemical and
biological modulation have been studied. Biochemical modulation of cytarabine
metabolism by fludarabine through up-regulation of deoxycytidine kinase activity led to
promising results [26]. In addition, by biological modulation, the remission rate of
patients treated with combined therapy, fludarabine plus granulocyte colony stimulating
factor (G-CSF), was greater (63 %) than therapy with fludarabine alone (41 %) [27].
Several other combined regimens were extensively studied.
1.1.3.1.

Combinations with DNA-damaging agents

The overall concept of combining DNA damaging agents with fludarabine relays
on the hypothesis that fludarabine inhibits the nucleotide excision repair process (NER)
induced by the damaging agents and thus enhances the cytotoxicity of these compounds.
Cyclophosphamide. Combination of fludarabine with cyclophosphamide has been
examined in 10 clinical trials. For example, in a phase III comparative trial, 207
treatment-naive patients with advanced CLL were treated with either fludarabine or in
combination with cyclophosphamide. The combination regimens resulted in significantly
higher overall response (OR) (94 versus 85 % with fludarabine alone) and complete
response (CR) (21 versus 9 % respectively) [28]. The main disadvantage associated with
this combination was the myelosuppression (neutropenia, thrombocytopenia and anemia).
Chlorambucil. Fludarabine plus chlorambucil was evaluated in four clinical trials, two
phase I/II trials and two large phase III trials. Collectively, the results from these studies
suggest that the combination does not produce a significant improvement in response rate
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or survival compared with fludarabine alone. Furthermore, the combined regimen was
associated with severe adverse effects [29,30].
Cyclophosphamide

and

mitoxantrone.

The

combination

of

fludarabine

with

cyclophosphamide and mitoxantrone was assed in one clinical trial. The OR was 78 %,
including 50 % CR and 28 % PR, but the incidences of myelosuppression and infection
were significantly higher.
Prednisone. Two studies of CLL patients were used to evaluate the efficacy of
fludarabine plus prednisone. The results show that the combination resulted in an OR of
80 %, no significant different from fludarabine alone (80 %). CR rate for fludarabine plus
prednisone was 23 %, significantly lower than for fludarabine alone (38 %). Together,
these results showed that fludarabine plus prednisone is no more effective than
fludarabine alone [31].
Other chemotherapeutic agents. Seven trials have investigated fludarabine in
combination with six other chemotherapeutic agents. Fludarabine plus mitoxantrone did
not markedly increase the response rate compared to fludarabine alone (OR was 77 %
and CR was 20 %) [32]. Fludarabine plus doxorubicin demonstrated no therapeutic
benefits and increased rates of opportunistic infections [33]. In contrary, a higher
response rate was achieved in a phase II study with fludarabine and epirubicin. (OR of 92
% and CR of 40 %). Also, adverse effects associated with this combined treatments were
relatively mild. These results were also confirmed in a phase III randomized trial (OR of
89% and CR of 26 %) [34]. There are three other fludarabine combination regimens
which have proved to be less effective than monotherapy with fludarabine: cytarabine,
cisplatin and dexamethasone [35-37].
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Collectively, these studies demonstrated that when fludarabine is given as a
component of combination therapies, clinical relevant effects are sometimes observed,
but also show that there is a need for further, more effective combinatory regimens.

1.2.

Base excision repair pathway
1.2.1. Overview
Base excision repair is the major system responsible for removal of damaged

DNA bases and repair of DNA single strand breaks generated spontaneously or induced
by exogenous DNA damaging factors such as ionizing radiation and alkylating agents
[38]. In brief, BER involves: (i) damaged base excision, (ii) incision at the resulting
abasic (AP) site, (iii) replacement of missing nucleotide, and (iv) sealing of the resulting
nick. Excision repair of the damaged base is initiated by a specific DNA glycosylase, the
enzyme responsible for the recognition and removal of damaged base by hydrolyzing the
glycosylic bond (the bound linking the base residue to the DNA sugar phosphate
backbone). Further, the AP site is recognize by AP endonuclease (APE) that will cleave
the phosphodiester bond 5’ to the AP site generating an single strand break containing a
5’-sugar phosphate. Several proteins are involved in processing of the modified 3’and 5’ends: DNA polymerase β (pol β), polynucleotide kinase (PNK), APE and aprataxin. After
restoring conventional 3’-hydroxyl and 5’-phosphate strand breaks ends, repair is
accomplished by either short or long -patch pathway. In the major BER pathway, shortpatch repair, pol β adds one nucleotide to the 3’-OH end of the strand break, thus filling
one nucleotide gap created during repair. The DNA ligase IIIα-XRCC1 heterodimer seals
the DNA end and completes the repair process (Figure 1-3) [39,40]. The minor BER
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pathway, long-patch acts to repair AP sites that have the sugar residue modified, e.g.
oxidized or reduced [41]. To initiate this pathway, pol β first adds one nucleotide to the 3’
end of the nick and than pol δ and ε add a few more nucleotides to generate part of a
single-stranded flap structure containing a 5’ sugar phosphate. This flap structure is
recognized and excised by flap endonuclease 1 (FEN1) and the DNA is finally ligated by
DNA ligase I. FEN1 activity is stimulated by proliferating cell nuclear antigen (PCNA)
[42]. Alternately, the repair process can be catalyzed by pol δ plus PCNA [41].
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Figure 1-3
The base excision repair pathway [39]
The proteins believed to be responsible for various reaction steps are shown. The detailed
mechanism is described in text. Short-patch BER is responsible for a single nucleotide
repair, whereas in long-patch BER, two to ten nucleotides are replaced.
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Base excision repair proteins:
DNA glycosylases. DNA glycosylases are responsible for initiating BER by catalyzing
hydrolysis of the C1’-N glycosylic bond to the damaged base and by removing the base,
generating an AP site. Ten glycosylases have been identified to have a role in mammalian
BER and their specificities are summarized in Tabel 1-I. DNA glycosylases can be
divided in two classes based on their mechanistic activity: mono-functional (i.e.
glycosylase activity only) such as UDG and bi-functional (i.e. glycosylase and β-lyase
activities) such as hOGG1 [43].

TABLE 1-I. Mammalian DNA Glycosylases and their substrates
Glycosylases

Bifunctional ?

Substrates

UNG2

No

U, 5FU.

Smug1

No

U, OHMeU

TDG

No

U:G, T:G, ethenoC

MBD4

No

U:G, T:G in CpG sites

OGG1

Yes

8oxoG:C, FapyA, FapyG

MYH

No

A:8oxoG

NTH1

Yes

Oxidised and fragmented pyrimidines (e.g. Tg, DHU)
Fapy

AAG (MPG)

No

3-meA, 7-meG, ethenoA, ethenoG, hypoxanthine

NEIL 1

Yes

FapyA, FapyG, dihydrouracil, thymine glycol, 8oxoG (low)

NEIl2

Yes

cytosine oxidation products (5-OHU, DHU)
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The crystal structures of many of the DNA glycosylases have been elucidated. They show
some similarities which suggests a common mode of action. The glycosylases gently
pinch the DNA while scanning it resulting in bending of DNA at the site of instability
caused by mismatching. This DNA bending combined with pushing from the enzyme
makes mismatch base to flip out of the DNA and to enter the binding site of the enzyme.
While in the binding site, the base bond to the sugar is cleaved by the enzyme. In Figure
1-4 is presented the enzymatic mechanism of UDG [44].
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Figure 1-4
Proposed mechanism for UDG cleavage of N-glycosyl bond [44]
The uracil base dissociates leading to an oxocarbenium cation intermediate (1 → 2).
Subsequent attack by water produces an apurinic/apyrimidinic (AP) site (2 → 3).
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AP endonucleases. An important step in BER pathway involves the cleavage of the AP
site by APE. APE is a multifunctional enzyme that is not involved only in BER, but also
functions as a reduction-oxidation factor to maintain transcription factors in an active
state. Extensive studies showed that mice nullzygous for APE gene are embryonic lethal
[45] and downregulation of APE levels in human cells using RNAi leads to accumulation
of AP sites, inhibiting DNA replication and generating apoptosis [46]. APE cleaves the
phosphodiester bonds in an Mg2+-dependent manner, leaving a 3’-hydroxyl group and a
5’-deoxyribose phosphate (dRP) group flanking the nucleotide gap.
BER DNA polymerases. The presence of an intermediate containing a 3’-hydroxyl
group acts as a substrate for DNA polymerase. In the short-patch BER pathway, DNA
synthesis is carried out by pol β [47,48]. Pol β contains two domains: a C-terminal
polymerase domain and an N-terminal dRP domain. Both domains are required for shortpatch BER. Processing of the single-strand breaks resulted by dRP lyase activity of pol β
is carried out through catalysis of a β-elimination reaction. This reaction is followed by a
polymerase activity to fill the nucleotide missing [49]. Pol β lacks any intrinsic proofreading activities. Pol β is ubiquitinously express in all tissues. It is also expressed
constitutively and without demonstrable cell-cycle dependence. The importance of this
enzyme for the cells was demonstrated using studies in mice. They showed that mice
nullizygous for pol β are non-viable and die early in embryogenesis [50].
DNA ligases. DNA ligase I and DNA ligase III are the main ligases involved in BER.
DNA ligase III exists as two isoforms: DNA ligase IIIα and DNA ligase IIIβ [51]. The
enzymatic activity of DNA ligase IIIα is dependent on interaction with XRCC1. DNA
ligase I is involved in long-patch BER pathway, but also plays a role in DNA replication
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[51]. Human cells containing DNA ligase I show hypersensitivity to DNA-damaging
agents [52].
XRCC1. XRCC1 is a multi-domain protein with an N-terminal DNA binding domain
and two BRCT (BRCA1 C-terminus) motifs. BRCT I contains the site of interaction with
PARP1 and BRCT II is involved in interaction with DNA ligase IIIα [53]. The nickbinding N-terminal domain of XRCC1 interacts with pol β, forming a tertiary complex
with the polymerase and nicked DNA. Cells deficient in XRCC1 show partial defect in
BER efficiency when compared to wild type. The importance of the XRCC1 gene for
cellular functioning is underlined by the fact its targeted knockout results in embryonic
lethality [54]. XRCC1 interacts also with PARP1, APE and PCNA.
Poly(ADP-ribose)polymerase, Polynucleotide kinase, Aprataxin. The role of PARP1
in BER is to bind to incised AP sites before any other repair proteins. In vitro repair
reactions carried out on absence of PARP1 result in increased nucleolytic degradation of
BER intermediates, thus it suggests that PARP1 functions to protect strand breaks and
repair intermediates from degradation or recombination [55]. Additionally, it has been
reported that the genome of PARP1 null mice shows an increased incidence of deletion
mutations upon DNA damage.
Polynucleotide kinase (PNK) in an enzyme involved in the processing of 5’-phosphate
and 3’-hydroxyl ends at single strand breaks. As part of the repair pathway, PNK
interacts with XRCC1, DNA ligase IIIα and pol β [56].
Aprataxin is a member of the HIT superfamily of nucleotide hydrolases/transferases.
Aprataxin interacts with XRCC1 and it is involved in the resolution of abortive DNA
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ligation intermediates by catalyzing the release of adenylate groups covalently linked to
5’-phosphate termini at single strand nicks [57].
1.2.2. Targeting BER to overcome drug resistance
Most chemotherapeutic agents cause cell death by damaging DNA. Some of this
agents, initially effective, develop resistance through repair capacities of the cancer cells.
Various preclinical studies suggest that BER represents an important target for anticancer
therapy as its inhibition has been shown to sensitizes cells to cytotoxic effects of different
alkylating agents. Several approaches have been developed. One direction was focused
on inhibiting BER by targeting APE. Up to date, two chemical compounds were isolated
(CRT0044876 and lucanthone) and shown to have APE inhibitory characteristics. By
combining these compounds with alkylating agents or methylating agents, significant
increase in cytotoxic activity against ovarian cancer cells has been measured [58,59]. A
second direction was focused on PARP1 inhibition. Even though the role of PARP1 in
BER is not fully understood, inhibition of PARP1 leads to inhibition of DNA repair and
promotes apoptosis in cancer cells. Currently, several PARP1 inhibitors are evaluated in
clinical trials in combination with certain anticancers agents (Tabel 1-II). One example of
this combined therapy is TMZ plus PARP1 inhibitor. It has been shown that when
PARP1 is inhibited, it remains bound to the SSB created by TMZ which triggers
apoptosis [60]. PAPR1 inhibitors enhance the cytotoxicity of DNA topoisomerase I
inhibitors, irinotecan and topotecan. They also enhance the cytotoxic effect of
radiotherapy, both in vitro and in vivo [61]. Several other combination strategies for
PARP1 inhibitors are under investigation.
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TABLE 1-II. PARP inhibitors currently in clinical trials
PARP inhibitor

Phase of trial

Subject group

AG-014699

I, II

Patients with malignant melanoma

KU 59436

I

Patients with advanced solid tumors

INO-1001

IB

Patients with advanced solid tumors

INO-1001

I

Patients with glioblastoma multiforme

BSI-201

I

Patients with advanced solid tumors

GPI 21016

I

Patients with advanced solid tumors

ABT-888

Pilot study

Patients

with

advanced

solid

tumors

and

lymphoid malignacies

A more promising strategy to enhance cytotoxic effect of chemotherapeutic agents by
targeting BER is the use of a small molecule, methoxyamine (MX) and its derivatives.
1.3.

Methoxyamine
1.3.1. Mechanism of action

Methoxyamine (MX) has been extensively studied as an inhibitor of BER. The action
of MX in inhibiting BER has been demonstrated (Figure 1-5): (a) MX binds to the
aldehyde group of the tautomeric open ring form of deoxyribose generated after removal
of the abnormal base by DNA glycosylase; (b) the reaction of MX with AP sites is faster
than APE reaction with the same site; (c) MX-bound AP sites reduce the APE cleavage
of the DNA backbone by more than 300-fold compared with the cleavage of the normal
AP site [62-65]. Chemotherapeutic agents such as temozolomide (TMZ) and 1,3-bis-(2chloroethyl)1-nitrosurea (BCNU) form AP sites due to removal of the drug-induced
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methylated purine by DNA glycosylase. BCNU alkylates DNA predominantly ( >90 %)
at N7 position of guanine. Repair of these lesions involves formammidopyrimidine-DNA
glycosylase (FPG) and 8-oxoguanine-DNA glycosylase (OGG1). Temozolomide
treatments result in methylation of N7 position of guanine (70 %) and of N3 position of
adenine (4 %). These lesions are removed from DNA by methylpurine glycosylase
(MPG) leading to formation of AP sites. Blocking the repair of these AP sites with MX
leads to accumulation of these cytotoxic sites (MX-bound AP-sites) in DNA [65]. MX
has been shown to augment the cytotoxicity of several DNA damaging agents in vitro and
also in xenograft studies [66,67]. MX is able to potentiate cytotoxicity in both MMRproficient and MMR-deficient cells [60]. MX is also able to overcome other resistance
factors such as the loss of p53 tumor suppressor function [65]. An example of effective
enhancement of cytotoxicity by MX is the combination with TMZ. This combined
treatment regimen was extensively studied in vitro and in vivo. In vivo, MX enhanced
antitumor effect of TMZ in several colon cancer cell lines that was associated with
significant apoptotic cell death and severe chromosomal aberrations (sister chromatin
exchange, DNA breakage and aneuploidity) [66]. In vitro, MX binds to the AP sites
formed by TMZ treatments to form MX-bound AP-sites. These sites cannot be repaired
by APE leading to apoptotic cell death. One molecular mechanism of cell death mediated
by MX-bound AP-MX is conversion of topoisomerase II into biotoxin, resulting in
enzyme-mediated DNA scission and cell death. [68]. MX was also shown to enhance
cytotoxicity of 5-iodo-2’deoxyuridine (IdUrd), a halogenated thymidine analog. [69].
Such results led to BER modulation to augment clinical response of cytotoxic agents
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currently used in the clinic. A Phase I clinical trial of MX in combination with TMZ is
currently in progress.
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Figure 1-5
Methoxyamine binds to the AP site and blocks APE cleavage [65]
Methoxyamine reacts with the aldehyde moiety of the open-ring form of the AP site
generated after removal of the damaged base by a DNA glycosylase. The MX-bound AP
sites formed are refractory to cleavage by APE.
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3’

Apoptosis

1.4.

Apoptotic cell death pathways
Apoptosis is in general characterized by distinct features and energy-dependent

biochemical mechanisms. Apoptosis is considered a vital component of normal cell
turnover, proper development and function of immune system, hormone-dependent
atrophy, embryonic development and chemical-induced cell death. The ability to
modulate the death of a cell it is recognized for its tremendous therapeutic potential. To
date, numerous studies have shown that there are two main apoptotic pathways: the
extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway. These
pathways converge on the same terminal, execution pathway [70].
1.4.1. Extrinsic (death receptor) pathway
The extrinsic pathway is characterized by transmembrane-receptor-mediated
interactions. The key players are the death receptors that are members of the tumor
necrosis factor (TNF) receptor gene superfamily. All members share a similar
cytoplasmatic domain called the “death domain” which plays an important role in
transferring the death signaling from the surface to intracellular signaling. Several ligands
and corresponding death receptors have been studied: FasL/FasR, TNFα/TNFR1,
Apo3L/DR, Apo2L/DR4 and Apo2L/DR5 [71,72]. Upon ligand binding, cytoplasmatic
adaptor proteins are recruited and will bind the receptor. These adaptor proteins will
associate with procaspase-8 through dimerization of the death effector domain. Following
this association, death-inducing signaling complex (DISC) is formed, resulting in autocatalytic activation of procaspase-8 [73]. Once caspase 8 is activated, the execution phase
of apoptosis is triggered (Figure 1-6).
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Figure 1-6
The extrinsic apoptotic pathway [74]
The extrinsic pathway begins outside the cell through the activation of specific proapoptotic receptors on the cell surface by specific molecules known as pro-apoptotic
ligands. The intracellular domains of these receptors, known as the 'death domains', bind
to the adaptor protein Fas-associated death domain (FADD), leading to the assembly of
the death-inducing signaling complex, or DISC, and recruitment and assembly of initiator
caspases 8 and 10. Caspases 8 and 10 are stimulated and undergo self processing,
releasing active enzyme molecules into the cytosol, where they activate caspases 3, 6, and
7, thereby converging on the intrinsic pathway.
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1.4.2. Intrinsic (mitochondrial) pathway
The intrinsic signaling pathway involves a variety of stimuli that result in
intracellular signals that act directly on targets within the cell and are mitochondrialinitiated events. These stimuli cause changes in the inner mitochondrial membrane that
will lead to opening of the mitochondrial permeability transition (MPT) pore, loss of the
mitochondrial transmembrane potential and release of the two groups of sequestered proapoptotic proteins from the intermembrane space to the cytosol [75]. The first group
contains cytochrome C, Smac/Diablo and a serine protease Htr2/Omi. Cytochrome c
binds and activates Apaf-1 and procaspase-9, forming a complex called “apoptosome”
(Figure 1-7) [76]. This complex formation leads to caspase-9 activation. Additionally,
Smac/Diablo and Htr2/Omi promote apoptosis by inhibiting IAP (inhibitors of apoptosis
proteins). The second group of pro-apoptotic proteins, AIF, endonuclease G and Caspaseactivated DNase (CAD), are release late from mitochondria, after the cell has committed
to die. AIF translocated to nucleus and cause DNA fragmentation into 50-300 kb pieces
and condensation of peripheral nuclear chromatin, known as stage I condensation [77].
Endonuclease G translocates to nucleus as well where it cleaves nuclear chromatin to
produce oligonucleosomal DNA fragments [78]. CAD translocates to nucleus where
leads to DNA fragmentation and a more advanced chromatin condensation. The control
and regulation of these mitochondrial events occurs through members of Bcl-2 family
proteins. These proteins can be either pro-apoptotic or antiapoptotic. To date, 25 genes
have been identified. The antiapoptotic proteins include Bcl-2, Bcl-xl, BAG, Bcl-xs. The
pro-apoptotic proteins include Bcl-10, Bax, Bad, Bim, Bik [79].
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Figure 1-7
The intrinsic (mitochondrial) apoptotic pathway [74]
The intrinsic pathway is initiated from within the cell. This is usually in response to
cellular signals resulting from DNA damage. This pathway involves release from the
mitochondria of pro-apoptotic proteins that activate caspase enzymes, which ultimately
trigger apoptosis.
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The intrinsic and extrinsic pathways converge to execution phase. This phase is
represented by the activation of execution caspases. Execution caspases activate
cyoplasmic endonuclease which degrades nuclear material, and protease that degrade the
nuclear and cytoskeletal proteins. Executioner caspases are: caspase-3, caspase-6 and
caspase-7. These caspases cleave various substrates such as PARP, cytokeratins, the
plasma membrane cytoskeletal protein alpha fodrin, and other, that cause the
morphological and biochemical changes in apoptotic cells [80].
1.4.2.1.

Mitochondrial DNA damage

Mitochondrial DNA (mtDNA) is a circular double-stranded genome, consists of
15,000-17,000 base pairs (bp) that codes for 13 subunits of the oxidative phosphorylation
system, 2 ribosomal RNAs (rRNAs), and 22 transfer RNAs (tRNAs) (Figure 1-8) [81]. It
is present in 100-10,000 copies per cells. MtDNA consists of predominantly of coding
DNA with exception of an 1100 bp long region that has mainly regulatory functions. The
DNA polymerase gamma (pol γ) is used for the replication of mtDNA. The replication is
in a D-loop mode due to different origins of replication on the two strands. One strand
begins to replicate first, displacing the other strand. This process continues until
replication reaches the origin of replication of the other strand, at which point the other
strand begins to replicate in the opposite direction.
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Figure 1-8
Mitochondrial DNA [81]
Human mtDNA encodes 13 polypeptides: 7 subunits - ND1, ND2, ND3, ND4, ND4L,
ND5, and ND6 - of Complex I (NADH-Coenzyme Q oxidoreductase); 1 subunit cytochrome b - of Complex III (CoQ-cytochrome c oxidoreductase), 3 subunits - COX I,
COX II, and COX III - of Complex IV (cytochrome c oxidase, or COX), and 2 subunits ATPase 6 and ATPase 8 - of Complex V (ATP synthase). It also encodes 2 rRNAs (in
green) and 22 tRNAs (in blue).
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Mitochondrial DNA transcription involves mtRNA polymerase, mitochondrial
transcription factor A and mitochondrial transcription factors B1 and B2. The proteins
assemble at the mitochondrial promoters and begin transcription. MtDNA has three
promoters, H1, H2 and L (heavy strand 1, heavy strand 2 and light strand promoters. The
H1 promoter transcribes the entire heavy strand, the L promoter transcribes the entire
light strand, while H2 promoter causes transcription of the two mitochondrial rRNAs.
MtDNA is very susceptible to damage from various sources such as free radicals
and chemotherapeutic agents which will lead to deletions, rearrangements, other
mutations or activation of apoptosis. Recent evidence suggests that mitochondria contain
DNA repair mechanisms.

There is evidence for base excision repair (BER), direct

damage reversal, mismatch repair, and recombinational repair mechanisms in
mitochondria, while nucleotide excision repair (NER), as we know it from nuclear repair,
is not present [82].
1.4.2.2.

Mitochondrial DNA base excision repair pathway

A simplified BER in mitochondria has been established but has not been
extensively characterized. Several BER enzymes such as uracil DNA glycosylase [83]
and AP endonuclease [84] have been detected in mitochondria (Figure 1-9). The
replication polymerase in mitochondria is γ (pol γ), and it has been demonstrated that
purified pol γ can also serve as a repair polymerase in mitochondria [85-87]. The ligase
involved in mitochondrial BER is believed to be an alternate splice variant of nuclear
DNA ligase III [84]. The pathway includes four distinct steps: lesion removal by a
glycosylase, abasic site processing by an AP endonuclease, insertion of a new nucleotide
by polymerase γ and ligation of the broken strand by DNA ligase.
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Figure 1-9
The short-patch mitochondrial BER [87]
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CHAPTER II
STATEMENT OF OBJECTIVES

Fludarabine is a widely used anti-tumor agent for the treatment of indolent
lymphoproliferative disorders. The inhibition of DNA replication via incorporation of Fara-ATP into DNA and subsequent chain termination is thought to be a significant
mechanism leading to fludarabine-induced cell death. However, the molecular aspects of
the cytotoxic action of fludarabine are not completely understood.
This work aims to expand the knowledge on the biochemical mechanisms of
fludarabine-induced cytotoxic effects. Fludarabine, a purine base analog, incorporates
into DNA and possibly acts as an abnormal base, triggering the activation of base
excision repair (BER) system. BER entails the combined effort of several repair proteins
(DNA glycosylases) that recognize and excise specific DNA damages, converting diverse
base lesions into a common intermediate, apurinic/apyrimidinic (AP) sites. Eventually the
damaged moiety is replaced with a normal nucleotide and DNA is restored back to its
original state. The potential involvement of BER (essential for both, nuclear and
mitochondrial DNA) in processing incorporated fludarabine was not previously
documented or explored. Moreover, once initiated BER could account for resistance to
fludarabine, since a functional active BER should be able to recognize and repair the
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specific DNA damage induced by the incorporated drug. It would be then only reasonable
to predict that BER inhibitors – e.g. methoxyamine (MX) – could enhance antineoplastic
activity of fludarabine and thus, a combination of fludarabine plus MX might represent a
new and effective therapeutic strategy. To test this series of suppositions, the following
specific aims were devised:

1. To demonstrate that BER enzymes are capable to recognize and initiate removal
of fludarabine incorporated into DNA (Chapter 3)
The working hypothesis for this aim is that at least one of the members of DNA
glycosylase family can recognize and excise incorporated fludarabine. An in vitro
screening for DNA glycosylase activity, employing various purified enzymes or whole
cell extracts and a synthesized 40-mer oligonucleotide substrate that contains fludarabine,
is performed. Subsequent kinetic studies to characterize the enzymatic activity of selected
glycosylase are carried out.
Identifying the glycosylase potentially implicated in fludarabine recognition is
significant for two main reasons: (i) it sustains the possibility that BER is involved in
processing incorporated fludarabine and (ii) it is critical for the subsequent molecular
studies, since more targeted experiments can be devised to investigate the eventual role of
BER in modulating fludarabine action.

2. To demonstrate BER involvement in fludarabine-induced damage and to
investigate the effect of MX on blocking the repair process (Chapter 4)
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Based on the structural similarities with the normal base and the primary action of
fludarabine to incorporate into DNA, the tested hypothesis is that incorporated
fludarabine, acting as an abnormal base in DNA, initiates BER. This hypothesis is
verified in cancer cell lines that are expressing or not the glycosylase identified in
specific aim 1. The experimental approach involves (i) a correlation of AP site formation
with concentrations of fludarabine

(first step in BER) and (ii) an examination of

expression of key BER proteins in a strategy of treatments with fludarabine alone.
Additionally, a new possibility to enhance fludarabine-induced damage by using
MX in combination with fludarabine is proposed. Hypothesis that MX is able to bind to
fludarabine-induced AP sites, thus further blocking the repair pathway is tested in human
tumor cell lines with different repair status and in several human tumor xenografts, by
assessing the toxicity induced by fludarabine alone or in combination with MX.
Two important findings are aimed here: (i) a first demonstration that in cells BER
can process incorporated fludarabine and (ii) insights into a new and promising drug
combination (fludarabine plus MX).

3. To delineate the contribution of mitochondrial apoptotic pathway in cell death
after fludarabine and MX exposure (Chapter 5)
The working hypothesis is that mitochondrial DNA is a target for fludarabine and
MX and thus, mitochondrial DNA damage mediates the apoptotic cell death.
Mitochondrial DNA damage – and more specifically AP site formation in
mitochondrial DNA – is characterized in fludarabine alone or fludarabine plus MX
treatments. Mitochondrial DNA damage is then correlated with known markers of
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programmed cell death to demonstrate that fludarabine targets the mitochondria and
promotes release of cytochrome c and other pro-apoptotic proteins, eventually triggering
caspase activation and the apoptotic process.
Valuable information suggesting a mitochondrial mediated apoptotic death after
fludarabine and MX treatments is obtained, which could place the mitochondrial
apoptotic pathway in the focus of future studies on the mechanisms of cell killing by
fludarabine.

4. To examine whether the combination of fludarabine and the BER inhibitor MX
can represent a new therapeutic strategy for improving the treatment of chronic
lymphocytic leukemia (CLL)
To confirm the hypothesis that combination treatment of fludarabine and MX has
greater antineoplastic activity when compared with single agents, modulation of
fludarabine activity by manipulating BER via MX is analyzed in a series of experiments
employing CLL patient samples. The MX enhancement of activity of fludarabine is
confirmed, since CLL cells are significantly more sensitive to the fludarabine in
combination with MX as assayed by cytotoxicity, apoptosis, and levels of DNA damage.
These studies show that through manipulation of the BER pathway, an increase in
response to fludarabine is achieved in CLL lymphocytes. The combination of fludarabine
plus MX represents a potential new clinical targeted therapy with lower toxicity to
normal cells.
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CHAPTER III
UDG IS A MAJOR DNA GLYCOSYLASE HAVING ACTIVITY ON
F:T MISPAIRS: IDENTIFYING A NEW TARGET FOR
FLUDARABINE

Abstract
Fludarabine primary cytotoxic mechanism of action is mediated by the
incorporation of F-ara-ATP into DNA leading to subsequent inhibition of DNA
replication. We hypothesized that the incorporation of F-ara-adenosine as an abnormal
base initiates the sequential repair cascade to produce AP sites through a DNA
glycosylase, the first step in BER. However, the molecular mechanism of BER to
process incorporated fludarabine is not known. In this in vitro study, using
oligonucleotide substrates containing F-ara-adenosine: thymidine mispairs (F:T), we
examined the cleavage activity of five purified DNA glycosylases. Our results showed
that only UDG can recognize F:T mispairs and excise 2-fluoroadenine from DNA,
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displaying a time- and concentration-dependent cleavage. Analysis of products of the
enzymatic reaction, as performed by LC-ESI-mass spectrometry revealed 2fluoroadenine as the cleaved product after reaction. Similarly, cleaved products of the
UDG enzymatic reaction were seen when the F-ara-A oligonucleotide substrate was
incubated with cell extracts from HL60 or Jurkat cells, as observed by electrophoresis
on denaturing acrylamide gels. To evaluate the relative substrate specificity of UDG,
the kinetics of excision of F-ara-A were compared with uracil in a double-stranded
oligonucleotide. The results show that, although the specificity of UDG for F-ara-A
residues is ~20-fold lower compared to uracil, F-ara-A is also a substrate for UDG.
Moreover, the cleavage activity of UDG in purified form or in cell extracts can be
abolished or reduced by UDG specific antibody or uracil glycosylase inhibitor,
respectively. Our results indicate that BER can process incorporated fludarabine
through the recognition and removal of 2-fluoroadenine in DNA by UDG.

3.1.

Introduction

Most chemotherapeutic agents currently used in the treatment of cancer, directly
or indirectly damage DNA causing direct base damage, misincorporation of analogs,
formation of single or double-strand breaks or interfering with DNA-interacting proteins.
The cellular response to these lesions is orchestrated in such way that the detection of the
damage leads to either repair or induction of cell death (1). The repair activity of the cell
plays an important role in cell sensitivity to anticancer agents (2,3). Thus, understanding
the repair machinery has provided the rationale for the development of new therapeutic
strategies to optimize the current ones. Among all the repair mechanisms that cells have
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developed, the most important one in removing non-bulky damaged nucleotides is base
excision repair pathway (BER) (4).
The BER pathway involves a series of sequential steps. These steps are: (1)
cleavage of the N-glycosidic bond by a DNA glycosylase resulting in the formation of
abasic site (AP site); (2) cleavage of the DNA backbone at the abasic site by apurinic/
apyrimidinic (AP) endonuclease; (3) polymerase insertion of a templated nucleotide at
the position of the abasic sites by DNA polymerase; (4) ligation of the nicked DNA by
DNA ligase (Figure 3-1.) (5-9) DNA glycosylases family, the enzymes that catalyze the
first step in BER has been extensively studied. Cells have many different DNA
glycosylases with different but sometimes overlapping specificities. Human cells at
present, have eleven distinct DNA glycosylases (UDG, SMUG1, TDG, MBD4, OGG1,
MYH, NTH1, MPG, NEL1, NEL2 (10,11). Two mechanistic classes of DNA glycosylase
are recognized: mono-functional (glycosylase activity only) such as UDG and bifunctional (glycosylase and β-lyase activity) such as OGG1 (12,13).
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Figure 3-1
Base excision repair pathway
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One structurally well-characterized DNA glycosylase and a prototype for other
DNA glycosylases that used base flipping mechanism is uracil DNA glycosylase (UDG).
The primary function of UDG is to remove mainly uracil from U/G mispairs. Other
substrates for this enzyme have been identified: 5-fluorouracil, isodialuric acid, 5hydroxyluracil and alloxan (14-17). There are two isoforms of this enzyme, a nuclear
form (UNG2, 313 amino acids) and a mitochondrial form (UNG1, 304 amino acids),
generated from UNG gene by alternative splicing and alternative transcription start point
(18). The two isoforms have identical catalytic domains. UDG crystal structure revealed
that the enzyme has a single α/β domain containing eight α-helices and a central fourstranded parallel and twisted β-sheet (Figure 3-2. A) (19,20). The catalytic mechanism of
action has been elucidated: DNA binds along a positively charged groove in the enzyme,
but the tight-fitting uracil-binding pocket located at the base of this groove is too deep
and narrow to allow binding of DNA-uracil unless it is ‘flipped out’ of DNA helix. While
the enzyme scans the minor-groove, it “pushes” the dUMP residue from the dsDNA base
stack via the major groove. This is associated with a compression of the DNA backbone
flanking the uracil and specific recognition of the 5’phosphate, deoxyribose and uracil by
UDG active-site residue which stabilizes the extra helical nucleotide confirmation. It
promotes condensation of the surrounding catalytic residue to form a productive complex
specific for uracil cleavage. In the UDG-DNA complex, both uracil and the deoxyribose
phosphate are rotated by nearly 180 ° from their normal positions. The mechanism is
described as nucleotide flipping (Figure 3-2. B) (21).
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Figure 3-2
UDG enzymatic mechanism [19,20,21]
A. UDG-DNA complex. B Backbone compression forced by three Ser–Pro-rich loops.
The loops of the Ser–Pro pinch (green) compress the uracil-containing DNA strand at the
phosphates 5' and 3' of the uracil nucleotide in the directions indicated by the arrows. C,
The UDG Ser–Pro pinch for initial damage detection. The initial UDG–DNA complex is
recreated by superimposing straight B-DNA (white) onto the kinked DNA seen in the cocrystal structures (orange), and the structure of uncomplexed wtUDG (stippled magenta
ribbons) onto the DNA-bound enzyme.
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Nucleotide analogs are a class of therapeutic agents that target DNA. Fludarabine,
an adenosine analog, is used for the treatment of hematological malignancies (22). Upon
being metabolized to its active triphosphate form, fludarabine is incorporated into DNA
(23). Among other molecular targets such as DNA polymerase and ribonucleotide
reductase (24-27), its incorporation may lead to activation of BER pathway. The
molecular mechanism of BER recognition and repair of the incorporated fludarabine has
not yet been elucidated.

3.1.1.

Hypothesis and Rationale

Research focus: To demonstrate that BER enzymes are capable to recognize and
initiate removal of fludarabine incorporated into DNA.
Given that the fludarabine mechanism of action is mediated by the incorporation
into DNA and the structural characteristics between fludarabine and adenosine (the
normal nucleotide) are similar but still different , we hypothesized that at least one of the
members of DNA glycosylase family, as part of BER pathway, can recognize and excise
incorporated fludarabine.
We examined in vitro the enzymatic requirements for removal of incorporated
fludarabine. Identifying the glycosylase potentially implicated in fludarabine recognition
is important for proving the possibility that BER process is involved in processing of
fludarabine induced-damage. It also set the stage for future, combinatory regimens.
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3.2.

Materials and Methods

3.2.1.

Cells and reagents

Human tumor cell lines, Jurkat (lymphoblastic), HL60 (myelocitic leukemic),
U937 (myelononocytic), were obtained from the American Type Culture Collection
(Rockville, MD) and cultured in proper mediums. Methoxyamine (MX) and 2fluoroadenine were purchased from Sigma Chemical Co (St. Louis, MO).

3.2.2.

Oligonucleotides and enzymes

The fluorescent HEX labeled 17-mer oligonucleotide 5’-[HEX]GTAAAACGAC
GGCCAGT-3’, the 21-mer 5’-ATTCGAGCTCGGTACCCGGGG-3’, the Cy5-labeled 40
mer oligonucleotide, 5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGT
TTTAC-3’ were purchased from Operon Biotechnologies (Huntsville, Alabama).
Complementary single-stranded oligonucleotides for U:G, U:T and G:T mispairs were
purchased from the same company:
5’[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGGGG-3’;
5’-[Cy5]CCCCGGGTACCGAGCTCGAATGCACTGGC CGTCGTTTTAC-3’ for U:G;
5’-[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGGGG-3’;
5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’ for U:T
and

5’-[HEX]GTAAAACGACGGCCAGTGGATTCGAGCTCGGTACCCGGGG-3’,

5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’ for G:T
mispairs. The duplex oligonucleotides were made by annealing the two complementary
strands in a reaction buffer containing 10 mM Tris-HCl, 50 mM KCl, 1 mm EDTA, by
heating at 95 ºC for 5 min and slowly cool it down at room temperature for 1 hour.
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The T4 polynucleotide kinase and T4 ligase were purchased from Invitrogen (Carlband,
CA). Human DNA polymerase β, E. Coli Uracil DNA glycosylase (UDG), mouse 3methyladenine DNA glycosylase (Aag), human 8-oxoGuanine DNA glycosylase
(OGG1), E. Coli Mut Y DNA glycosylase (Mut Y), Thymidine DNA glycosylase (TDG)
and human AP endonuclease were purchased from Trevigen (Gaithersburg, MD).

3.2.3.

Preparation of oligonucleotide substrates containing fludarabine

The procedure to construct oligonucleotide substrate containing an insertion of
F-ara-A was performed as described by Yang et al (8) with modifications. A fluorescent
HEX-labeled oligonucleotide, 5’-[HEX]GTAAAACGACGGCCAGT-3’ (17-mer) and
an oligonucleotide of 5’-ATTCGAGCTCGGTACCCGGGG-3’ (21-mer) were annealed
to a complementary Cy5-labeled oligonucleotide (Operon Biotechnologies, Huntsville,
Alabama),
5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’(40mer).
The double stranded oligonucleotides with a gap of two nucleotides at position 18 and
19 were generated:
5’ [HEX] GTAAAACGACGGCCAGT--ATTCGAGCTCGGTACCCGGGG
3’ CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC [Cy5]
The oligonucleotides were incubated with dGTP and DNA polymerase β, and either
dATP or F-ara-ATP (Trevigen, Gaithersburg, MD) for 1 hr at 37 °C. After precipitation,
the reactants were then incubated with T4 DNA ligase (Invitrogen, Carlband, CA) in a
reaction buffer containing 50 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 1 mM ATP, 1mM
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DTT at 14 ºC for 18 hrs, producing a 40-mer oligonucleotide substrate containing either
a normal adenine (A) or a fludarabine (B) at position 19:
A.

5’ [HEX]GTAAAACGACGGCCAGTGAATTCGAGCTCGGTACCCGGGG
3’CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC[Cy5]

B.

5’ [HEX]GTAAAACGACGGCCAGTGFATTCGAGCTCGGTACCCGGGG
3’ CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC[Cy5]

Given that uracil base in DNA in vitro efficiently activates UDG excision-activity (32),
the oligonucleotide substrates containing either uracil to thymine (U:T) or uracil to
guanine (U:G) base pair at position 19 were constructed as well. These oligonuleotides
were used as the control substrates to standardize UDG activity and specificity in vitro
assay.

3.2.4.

DNA glycosylase/APE assay

The assay mixture for DNA glycosylase activity contained various Units (from 020 Units) of purified enzymes and 4 pmol of the fluorescent labeled oligonucleotide
duplex in 20 µl reaction buffer containing 1 mM EDTA, 1 mM dithiothreitol (DTT), and
20 mM Tris-HCl (pH 8.0). DNA glycosylase reaction was stopped at 95°C for 5 min after
excising 2’-fluoroadenine (F-Ade) from oligonucleotide, resultant abasic sites were
incised by 1 Unit of APE1 treatment at 37 °C for 30 min. Reaction products were resolved
by electrophoresis through 20 % denaturing polyacrylamide gels (7 M urea, 1x Trisborate-EDTA) and visualized by using a Typhoon 9200 fluorescent Imager (Amersham
BioScience, Piscarawat, NJ). Fluorescent density was quantified using ImageQuant
software.
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3.2.5.

Enzyme kinetic assays

To calculate enzyme kinetics parameters UDG was incubated with substrates
(F:T, U:G and U:T) concentrations ranging from 10 to 600 nM, in the presence of APE1
(1unit) for 30 min at 37 °C, in a volume of 100 μL. Kinetics parameters were determined
using Michaelis-Menten fit and Lineweaver –Burk plots based on the levels of products
produced by the reaction of oligonucleotide with UDG/APE1.

3.2.6.

Detection and quantification of 2-fluoroadenine using LC-ESI mass

spectrometer
The 2-fluoroadenine standard solutions were prepared by serial dilution of 2fluoroadenine stock solution (1 mg 2-fluoroadenine per mL of 1 M HCl) in the enzyme
reaction buffer (containing 29 mM Tris-HCl, 1.8 mM EDTA, 1.1 mM DTT, 42 mM
NaCl, 3.3 mM KCl, 0.013 mg/mL BSA, and 3.3% glycerol, at pH 8.0). The mobile
phase was an aqueous solution 20% methanol and 0.1% formic acid. UDG glycosylase
reaction product sample (obtained as describe above, by incubating B oligonucleotide
substrate with purified UDG) and 2-fluoroadenine standards were pretreated by solidphase extraction using Waters Oasis® HLB cartridges (3 cc). Prior to the sample loading,
the cartridge was equilibrated with 3.0 mL of methanol, followed by 3.0 mL of 0.1 M
phosphate buffer (pH 8.0). 0.6 mL of sample or standard was diluted with equal volume
of 0.1 M phosphate buffer (pH 8.0) and loaded to the cartridge. The cartridge was washed
with 4.0 mL of deionized water and the retained 2-fluoroadenine was eluted with 10%
formic acid in methanol. The eluent was evaporated to dryness in a ThermoSavant DNA
120 SpeedVac®. Both the sample and the standards were six times concentrated by
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reconstitution in 100 μL deionized water.
An AgilentTM 1100 series HPLC system and a BrukerTM esquire HCT® ESI-ion-trap mass
spectrometer were used for this work. During an analysis, 20-μL sample was injected
into the system. The analytical separation was carried out on a Waters YMC-AQ®
Column (2.0×50 mm, 5 μm) by isocratic elution with the mobile phase at a flow rate of
0.1 mL/min. The mass spectrometer was operated under the following conditions:
positive ionization mode; scan range,

m/z = 140-158; scan speed, 8,100 m/z s-1;

nebulizer flow, 18.0 psi; drying gas flow, 5.0 L/min; drying temperature, 350oC;
capillary, 4.0 kV; skimmer, 40.0 V; ion charge control (ICC) target, 6,000; maximum
accumulation time, 100.00 ms; spectra averages, 10; rolling averages, 1. The protonated
2-fluoroadenine ion at m/z of 154 was used for the detection of 2-fluoroadenine.

3.2.7.

AP site assay

The AP sites were measured using ARP (aldehyde reactive probe) reagent. The
assay was performed as previously described with minor modifications (28-30). DNA (10
μg) was incubated with 15 µl of 1 mM ARP (Dojindo Laboratories, Kumamoto, Japan) in
150 µl PBS solution at 37 ºC for 15 min. DNA was then precipitated with 400 µl ice-cold
ethanol (100%) at -20 ºC for 20 min and washed with 70% ethanol. DNA was dried at
room temperature for 30 min and then resuspended in TE buffer to achieve a final
concentration of 0.3 μg/100 µl. The ARP-labeled DNA was then heat-denatured at 100 ºC
for 5 min, quickly chilled on ice and mixed with an equal amount of 2 M ammonium
acetate. The DNA was then immobilized on BA-S 85 nitrocellulose membrane
(Schleicher and Schuell, Dassel, Germany) using a minifold II vacuum filter device
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(Schleicher and Schuell, Dassel, Germany). The membrane was baked at 80 ºC for 1 hr
and incubated with 0.25% BSA/PBS containing streptavidin-conjugated horseradish
peroxidase (BioGenex, SanRamon, CA) at room temperature for 40 min with gentle
shaking. ARP-labeled AP sites were visualized by chemiluminescence (Amersham Corp,
Piscataway, NJ) followed by quantitative densitometry using NIH ImageJ software.

3.3.

Results

3.3.1.

UDG is a DNA glycosylase having activity on F:T mispairs

In order to examine whether incorporation of fludarabine residue into DNA can be
recognized and removed by BER mechanism, we constructed oligonucleotide substrates
containing a F-ara-A:T base pair (Figure 3-3. A) and examined the activity of five
purified DNA glycosylases, including UDG, AAG, TDG, OGG and Mut Y, excising Fara-A from oligonucleotide substrates (Figure 3-3.B), which is the first step of BER
pathway. Results revealed that among these glycosylases, only UDG displayed the
glycosylase activity to excise 2-fluoroadenine (F-Ade), producing a small fragment (∼18
mer) after incubation with APE1 to incise the DNA backbone. No cleavage was seen as
expected, when UDG was incubated with oligonucleotide containing a normal base-pair
of A to T at position 19. To further confirm the specific role of UDG in recognition and
removal of F-Ade, several experiments were performed. First, dose and time dependent
assessment of UDG activity excising F-Ade from oligonucleotide duplex were examined
and showed that the increased levels of cleaved fragments were proportionally correlated
with both the concentrations of UDG and the duration of enzymatic reaction (Figure 33.C). Second, to clarify that UDG excised F-Ade as an abnormal base and this excision
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was not due to the molecules of arabinose, an ara-Adenine-ATP was inserted into
oligonucleotide at position 19 instead of F-ara-A, and then UDG cleavage activity was
examined with this substrate. Results clearly showed that UDG had no activity to remove
ara-Adenine, leaving entire 40-mer oligonucleotide substrates (Figure 3-3.C). The results
indicated that the molecule of arabinose sugar could not stimulate the UDG excision
activity. Third, to verify that UDG removed base was 2-fluoroadenine (F-Ade), mass
spectro-analysis for F-Ade released from F:T oligonucleotide substrates after UDG
reaction was developed. After the reaction of UDG with F:T oligonucleotide substrates,
reaction products were collected and extracted with Waters Oasis® HLB solid-phase
extraction cartridge (3 ml) and concentrated for 6 times. F-Ade standards were prepared
by spiking F-Ade in the reaction buffer, and extracted and concentrated with the same
procedures used to prepare samples of UDG reaction. Analytical separation was carried
out on Waters YMC-AQ® Column (2.0×50 mm, 5 μm particle size with 120 Ǻ pore size)
by isocratic elution with the mobile phase (i.e., 20 % methanol with 0.1 % formic acid) at
a flow rate of 0.1 ml/min. As shown in Figure 3-2. D, F-Ade in UDG reaction buffer was
detected by ESI-IT mass spectrometer (c), which was confirmed by standards of 2fluoroadenine (a, b). Samples containing F:T substrate but without UDG showed no
detectable F-Ade (d).
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Figure 3-3
Double-stranded DNA oligonucleotide containing
F:T mispairs is a substrate for UDG
A, Schematic diagram represents the preparation of oligonucleotide substrates containing
F:T mispairs and the products of reaction of DNA glycosylase/APE with the
oligonucleotide substrates. B, Oligonucleotide duplex containing F-ara A (F:T) was
incubated with 5 DNA glycosylases ( UDG, OGG, TDG, AAG and MutY) at 37 ºC for 1
hr and followed by incubation with APE1 at 37 ºC for 30 min. Reaction products were
resolved by electrophoresis through denaturing 20 % polyacrylamine gels. C, UDG has
the activity excising F-Ade in a dose and time dependent fashion, but it has no activity to
cleave the substrates containing either A:T or ara-A:T. D, Identification of reaction
product of UDG on F:T substrate by HPLC-ESI-mass spectrometer. Schematic diagram
of the enzymatic reaction with the hydrolysis of the N-glycosydic bound between
arabinose and 2-fluoroadenine residue. UDG reaction samples were analyzed after
incubation of F:T substrate with UDG for 3 hrs.
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3.3.2.

Enzymatic kinetics of UDG activity excising 2-fluoroadenine from
double stranded oligonucleotide

To characterize UDG activity excising F-Ade, kinetic analysis was performed
using a 40-base oligonucleotide duplex containing either F:T or U:G, or U:T base pairs.
In this assay U:G oligonucleotide as the specific substrate of UDG was used to
standardize enzymatic activity. U:T substrates were used as controls to examine whether
T in an opposite strand affects UDG activity in comparison with U:G. Given that the
removal of the target base from 40-mer double-stranded oligonucleotide generated an AP
site that was incised by APE1, resulting in a fragment (∼18 mer), the UDG activity was
measured based on the levels of cleaved products (Figure 3-3.C). As shown in Figure 34.A, when 5 units of purified UDG and 4 pmol of either F:T or U:G substrates were used
for reaction, enzyme-catalyzed reactions were saturable, their rate of catalysis does not
show a linear response to increasing substrate. UDG produced products at a linear initial
rate followed by a slower rate at later time points. In comparison with uracil substrates,
the rate of UDG excising F-Ade was much slower, Vmax was 0.51 nM/min compared to
3.62 and 6.31 nM/min for U:G and U:T substrates respectively (Table 3-I). The products
of F-Ade were much lower than uracil excised by UDG, even after increased
concentrations of UDG (up to 20 units, Figure 3-4. B) and prolonged reaction time (60
min, Figure 3-4. C). The kinetic parameters of excision of uracil or F-Ade from
oligonucleotide substrates using purified UDG were shown in Table 3-I. It was noted that
the rate of turnover (Kcat) of UDG against U:G or U:T was high, about 7-12-fold faster
than that against F:T. The specificity constant (Kcat/Km) of UDG for F-Ade was 19-fold
lower than for uracil excised from either U:T or U:G oligonucleotide substrates. Data
indicate that F-ara-A is the substrate of UDG, but with low enzymatic specificity.

74

Figure 3-4
Enzymatic kinetics of UDG activity to excise 2-fluororadenine or uracil from
oligonucleotides containing F:T, U:T and U:G mispairs
A, The UDG catalyzed reaction: relation between the concentration of substrate and rate.
UDG was incubated with increasing concentrations of F:T or U:G substrate (10-600 nM)
for 30 min at 37 ºC in the presence of APE1 (1U). The cleavage products were analyzed
by 20 % denaturing polyacrylamide gel electrophoresis. The velocities of the reactions
were plotted against the substrates concentrations using Michaelis-Menten fit. Each point
represents the mean value from at least three independent experiments. B, Left panel:
Enzymatic activity of UDG was measured as a function of enzyme concentration (0-20
units) and the substrates (4 pmols) at 37 ºC for 1 hr. Right panel: Enzymatic activity of
UDG (5 units) was measured as a function of reaction time (0-60 min). Results are
representative of at least three independent experiments.
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Table 3-I: The kinetic parameters of uracil or F-Ade excision from oligonucleotide
substrates using purified UDG

substrate

Km
(nM)

Vmax
(nM/min)

Kcat
(min-1)

Kcat/Km
(x10-3 min-1 nM-1)

U:G

122 ± 43

3.617 ± 0.11

0.723 ± 0.11

5.92 ± 1.23

U:T

221 ± 19

6.314 ± 0.50

1.260 ± 0.07

5.70 ± 0.29

F:T

340 ± 89

0.514 ± 0.03

0.102 ± 0.02

0.30 ± 0.01
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3.3.3. Characterization of UDG glycosylase activity in cell extracts for
excising F:T mismatch
We next examined the ability of DNA glycosylases in cell to recognize and excise
F-ara-A from the oligonucleotide substrates. As shown in Figure 3-5. A and B,
oligonucleotide duplex containing F:T base pair was fragmented and the cleaved products
were increased proportionally with the concentrations of cell extracts from HL60
leukemia or Jurkat lymphoma cells (Figure 3-5. A, B). To further clarify the UDG
cleavage activity of F-Ade in cells, the Uracil Glycosylase Inhibitor (Ugi, NewEngland
Biolabs, Ipswich, MA) was used to inhibit UDG from cell extract. Ugi has been shown to
bind and form a tight complex with UDG (E. Coli or human), thus inhibiting UDG
activity (31,32).
As illustrated in Figure 3-5. C, the glycosylase activity of UDG both purified and
cellular enzyme on F-Ade from oligonucleotide substrates was completely inhibited after
pre-incubated with Ugi. Similarly, the UDG antibody was added in cell extracts from
HL60 cells prior to the reaction with substrates in order to specifically reduce UDG
activity, the reduction of UDG activity was seen by the decrease in cleaved products
which was correlated to the increase in the concentration of UDG antibodies. The UDG
antibody at concentrations of 10 - 20 µg/ml resulted in 80-90 % reduction of the cleaved
fragments compared to that produced by cell extracts containing entire UDG activity
(Figure 3-5. D). In contrast, cell extracts efficiently and completely excised uracil from
inserted strand of oligonucleotide (U:T), even at low protein concentrations (2.5 μg),
showing the cleaved fragments with strong density of green fluorescence and a intact
complemented oligonucleotide (40-mer) labeled with Cy5 (red). Reduced activity of
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UDG for excision of uracil was only seen when UDG-antibody was used up to high
concentrations (20 μg/ml). These results indicate that in human cells, uracil is the
common substrate for UDG. UDG antibody did not completely abolish UDG activity in
cell extracts, suggesting that in cell UDG is not a sole glycosylase to remove uracil from
DNA.
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Figure 3-5
Cleavage of oligonucleotide containing F:T by UDG
in cell extracts from HL60 and Jurkat cells
Oligonucleotide duplex containing F:T or U:T base-pair was incubated with various
concentrations of cell extracts (2.5- 40 μg) at 37 ºC for 30 min. The products of reaction
were analyzed by electrophoresis on 20 % denaturating polyacrylamide gel. A, HL-60
cells B, Jurkat cell C, UDG activity in cell extracts was inhibited by Ugi (Ugi was preincubated with cell extracts at 37 ºC for 30 min). D, UDG activity in cell extracts from
HL-60 cells was reduced by UDG specific antibody. Results are representative of at least
three independent experiments.
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U:T

3.3.4. The formation of abasic sites of arabinosyl nucleotides (ara-AP site)
after UDG cleavage of 2-fluoroadenine
Studies in vitro and ex vivo using oligonucleotide demonstrated that F-ara-A
residues in DNA were recognized and removed by UDG. However, it is not clear whether
the BER process of fludarabine occurs in cells. Thus, to detect the formation of ara-AP
sites is like confirming the initial step of BER in process of incorporated fludarabine in
DNA. We have measured AP sites using an aldehyde reactive probe reagent (ARP). ARP
has been demonstrated to bind to an aldehyde group in an AP site of the natural
deoxyribosyl sugar. However, we do not know whether the AP site of an arabinosyl sugar
can be detected by ARP. Therefore, in this study, ARP was the first time used to measure
ara-AP sites induced by fludarabine. A 40 mer oligonucleotide containing either F:T
mispair, A:T normal base pairing or U:T mispairs were reacted with purified UDG for 30
min, at 37 °C. The reaction was stopped and the DNA was extracted using ethanol. The
extract DNA duplex was labeled with ARP and the ara-AP sites were quantitated. As
shown in the Figure 3-6. when the normal, A:T oligonucleotide was reacted with UDG,
no AP sites were detected due to lack of enzymatic cleavage by UDG. In contrast, when
40 mer double stranded oligo containing F:T mispairs was incubated with UDG and
labeled, we detected AP sites. The levels of AP sites formed were lower that those
obtained using U:T substrate, as the control substrate.
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Figure 3-6
Ara-AP sites formed by UDG using substrate containing F:T mispairs
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3.4.

Discussion

In the present chapter we have demonstrated that: (i) among the five purified
DNA glycosylases tested, UDG was identified as the enzyme responsible for recognition
and removal of fludarabine incorporated in a synthesized 40-mer double stranded
oligonucleotide, (ii) kinetic studies have shown that F-ara-A is a substrate for UDG with
a lower specificity of the enzyme for this substrate and (iii) UDG was also responsible for
cleavage of fludarabine when whole tumor cell extracts were used.
DNA glycosylases remove a large number of cytotoxic bases from DNA. Some of
the enzymes have narrow specificities, whereas most can remove a large variety of
structural different bases. Noteworthy, some glycosylases have overlapping substrate
specificities which serve as a backup function (11). Using oligonucleotide substrates
containing F-ara-A residues, we demonstrated that in vitro and ex vivo purified UDG
excised incorporated F-ara-A from DNA, showing a direct relationship between the UDG
activity and the levels of excision of incorporated F-ara-A. By determining the enzyme
kinetic parameters, we confirmed that UDG is active against F-ara-A, but with a 19-folds
lower catalytic efficiency when compared with the UDG specific substrate, uracil.
Furthermore, using human cell extracts that were either depleted of the enzyme, either
with UDG activity altered with a specific inhibitor (31,32), we confirmed that the
cleavage of the F-ara-A is initiated by UDG.
Furthermore, the available evidence (J. Biol. Chem. 265: 16617-16625, 1990)
demonstrated that following its incorporation into the 3' terminus, the fludarabine
nucleotide is a poor substrate for addition of a subsequent nucleotide. Thus, evaluating
the activity of UDG against a substrate that contains the analogues at the 3’ position
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would model the other portion of the lesions that occur in whole cells. Even though this
question was not answered in vitro, our in vivo experimental approach and results
presented in Chapter 4 confirmed the role of UDG in removal of incorporated
fludarabine, regardless of possible locations of incorporated fludarabine.
Previous research has characterized the details of the chemical mechanism by
which UDG catalysis the removal of uracil residues from the DNA strand. The catalytic
unit of the enzyme gains access to the glycosidic bond by flipping the target nucleotide
out of the DNA helix. The very specific interaction between the active site of the enzyme
and the target lesion weaken the glycosidic bond, allowing rapid hydrolysis (11,20). One
could assume that UDG catalysis fludarabine-base removal by a similar mechanism.
In the case of fludarabine molecule both the sugar moiety and the base are
modified when compared with common nucleotide structure. The sugar moiety of
fludarabine is arabinose, while the base part contains a fluorine substitute in the second
position of the adenine ring. Considering these differences, we decided to test the
eventual involvement of the sugar. Thus, we synthesized a 40 mer oligonucleotide
(AraA:T) containing the sugar moiety of fludarabine attached to the adenine, the common
unmodified base (of adenosine). Studies using AraA:T substrate and purified UDG have
demonstrated that the sugar moiety of the fludarabine molecule does not participate in
UDG catalytic mechanism.
The base contained in fludarabine molecule is not the typical pyrimidinic
substrate for UDG. Still, we believe that the presence of fluorine substitute at the second
position of the adenine ring is a key structural feature for UDG activity on fludarabine.
Previous studies have shown that indeed, other molecules containing fluorine substitutes
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interact with UDG. For instance, 5-flurouridine is as substrate for UDG while
gemcitabine (the hydrogens on the 2' carbons of deoxycytidine are substituted with
fluorines) is able to inhibit the enzyme (33, 34).
Future studies involving crystal structure of human UDG bound to DNA
containing F-ara-A will be focus on elucidating how UDG recognizes and removes
fludarabine base and establish the role of the fluorine substitute in the biochemical
mechanism of the enzymatic reaction. Also, considering that we did not test all eleven
DNA N-glycosylases identified in mammalian cells, we could not rule out the possibility
that other glycosylases may be capable to excise F-ara-A from DNA in cells.
In summary, our in vitro tests suggest that UDG is the major DNA glycosylase
involved in excision of incorporated F-ara-A. In Chapter 4 of this material we present
our in vivo experimental approach and results underlying the importance of UDG in
response to fludarabine treatments.
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CHAPTER IV
TARGETING BASE EXCISION REPAIR BY METHOXYAMINE
ENHANCES FLUDARABINE INDUCED CELL DEATH

Abstract
Fludarabine is a widely used anticancer drug. The inhibition of DNA replication
via incorporation of F-ara-ATP into DNA and subsequent chain termination is thought to
be its primary cytotoxic action. Here, AP (apurinic/apyrimidinic) site as a new target of
fludarabine was identified and a novel therapeutic strategy combining fludarabine with
methoxyamine (MX), an agent that blocks BER through its binding to AP site, was
examined. This strategy rests on the hypothesis that the incorporation of fludarabine into
DNA activates BER pathway to process F-ara-A as an abnormal base and to generate an
ara-AP site, which is the target for MX. In cells, we found that formation of ara-AP sites
was increased proportionally with concentrations and exposure time of fludarabine and
that MX efficiently bound these ara-AP sites to form stable DNA lesions that have the
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potential to interrupt BER mechanism, leading to cell death. Moreover, MX markedly
enhanced fludarabine induced cytotoxic effect in tumor cells and therapeutic effect in
human tumor xenografts. Taken together, our findings indicate for the first time that in
cell BER can process incorporated fludarabine. They also provide insights into possible
leads to new and promising therapeutic strategies to enhance the antineoplastic activity of
fludarabine.

4.1.

Introduction
Fludarabine (2-fluoroadenine 9-β-D-arabinofuranoside-monophosphate), a purine

nucleoside analogue, is effective for the treatment of indolent lymphoproliferative
disorders such as acute myelogenous leukemia, acute and chronic lymphocytic leukemia
and low-grade non-Hodgkin’s lymphoma (1-4).
In cell, fludarabine (F-ara-A) is rapidly converted to the triphosphate species (Fara-ATP), which is the active form to incorporate into DNA and RNA strands (5). The
incorporated F-ara-A serves as a poor substrate for DNA replication enzymes, leading to
the inhibition of DNA replication. Several related molecular targets have been identified,
including ribonucleotide reductase, DNA polymerases α, β, γ, and ε, DNA primase, and
DNA ligase (6-8). Therefore, the primary action of fludarabine is thought to affect
replicating cells (9, 10). In addition, fludarabine induced inhibition of ribonucleotide
reductase results in depletion and imbalance of the deoxynucleotide pools required for
DNA repair and synthesis, subsequently may favor itself and other mismatched
nucleotides to incorporate into newly synthesized DNA strand. Collectively, stalling DNA
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replication, chain termination and free DNA ends also trigger apoptosis, leading to cell
death.
Given that the primary action of fludarabine is through its incorporation into
DNA, we hypothesize that incorporated F-ara-A seen as an abnormal base in DNA
activates base excision repair (BER). BER is the major DNA repair pathway to process
small base modifications generated by mis-insertions from imbalanced nucleotide pool,
deamination of cytosine to uracil, environmental mutagens, or anticancer agents (11).
BER pathway is prototypically initiated by a DNA glycosylase to remove a specific base
lesion and to generate an apurinic/apyrimidinic or abasic site (AP site) (12, 13). The AP
endonuclease (APE) is responsible for repair of the resultant AP sites by incising the
phosphodiester backbone of damaged DNA immediately 5' to an abasic site, leading to
the formation of a 3’-hydroxyl residue and a 5’-deoxyribose phosphate (5’-dRP). In
mammalian cells completion of BER occurs via two pathways, short-patch (single
nucleotide) or long-patch (2-10 nucleotides) repair, depending on the ability to remove the
5’-dRP and to complete repair syntheses (14,15). In the short-patch pathway, DNA
polymerase β removes the 5’-dRP residue and fills one nucleotide in the gap, which is
then sealed by a DNA ligase III (16). In the alternative long patch BER process, the 5’deoxyribosephosphate flap structure is excised by flap endonuclease (FEN1), DNA repair
synthesis and strand displacement are done by polymerase β, δ/ε (17-20). BER is the most
efficient repair mechanism to repair a variety of base lesions. Thus, while BER protects
cell from DNA damage, it also causes cell resistance to anticancer agents that produce
DNA lesions repaired by BER (21). To overcome BER conferred drug resistance,
methoxyamine (MX) has been studied (22, 23) and developed as an active inhibitor of
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BER. The specific action of MX is to specifically react with an aldehyde group in the
sugar moiety left at an AP site and to form a MX-bound AP-site. This structural modified
AP site is refractory to the repair activity of APE in BER pathway, resulting in the
persistence of the DNA lesion (17). MX has been demonstrated to enhance therapeutic
efficacy of different alkylating therapeutic agents (24-31) and currently is being evaluated
in clinical trials for its therapeutic value.

4.1.1. Hypothesis and Rationale
Research focus: To demonstrate BER involvement in fludarabine-induced damage
and to investigate the effect of MX on blocking the repair process
In this work BER response to fludarabine-induced DNA damage was determined.
Based on the structural differences between fludarabine and adenosine (the normal
nucleotide), we hypothesized that incorporated fludarabine in DNA triggers activation of
BER pathway. This leads to the subsequent hypothesis that methoxyamine, a known
inhibitor of BER, blocks fludarabine induced BER response and thus, enhances
fludarabine cytotoxicity.
We examined whether incorporated fludarabine is a substrate for BER and tested
whether blockage of BER by MX can potentiate fludarabine cytotoxicity in vitro and in
human tumor xenografts. Our results support our hypotheses and reveal the role of BER
activity in cellular sensitivity to fludarabine. These data provide a rationale for the clinical
development of fludarabine and MX in the treatment of hematological malignancies.
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Figure 4-1.
Working model: BER response to Fludarabine-induced DNA damage
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4.2.

Materials and Methods

4.2.1.

Cells and reagents

Human tumor cell lines, Jurkat (lymphoblastic), HL60 (myelocitic leukemic),
U937 (myelononocytic), SW480 and RKO (colon cancer) used in these studies were
obtained from the American Type Culture Collection (Rockville, MD) and cultured in
proper mediums. DLD1/UDG-/- cells were kindly provided by Dr. Sanford Markowitz.
Fludarabine was obtained from Berlex Laboratories (Richmond, CA) and freshly
prepared with mediums (containing alkaline phosphatase) for the treatment.
Methoxyamine (MX) was purchased from Sigma Chemical Co (St. Louis, MO). MX was
dissolved in sterilized water (pH 7.0) and stock solution (2.5 M) was stored at -20 ºC.

4.2.2.

AP site assay

The AP sites were measured using ARP (aldehyde reactive probe) reagent that
reacts with an aldehyde group at an AP sites and competes with MX to bind to AP sites.
Therefore, this reagent only detects MX-free AP sites. The assay was performed as
previously described with minor modifications (24, 32-34). Briefly, cells (2x106) were
plated and exposed to fludarabine (0-20 µM) with or without MX (3 mM). Cells were
collected at 24 hr after treatment and dose-dependent AP sites were measured.
Alternatively, for the time-dependent assay, cells were exposed to 5 µM fludarabine with
or without MX (3 mM) for a period of 72 hrs. Cells were harvested at 12, 24, 48 and 72
hr, respectively. After extracting by phenol (Fischer Scientific, Fair Lawn, NJ) and
chloroform (Sigma-Aldrich, St Louis, MO), DNA (10 g) was incubated with 15 µL of 1
mM ARP (Dojindo Laboratories, Kumamoto, Japan) in 150 µL PBS solution at 37 ºC for
15 min. DNA was then precipitated with 400 µL ice-cold ethanol (100 %) at -20 ºC,
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overnight and washed with 70% ethanol. DNA was dried at room temperature for 30 min
and then resuspended in TE buffer to achieve a final concentration of 0.3 g/100 µL. The
ARP-labeled DNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on ice
and mixed with an equal amount of 2 M ammonium acetate. The DNA was then
immobilized on BAS 85 nitrocellulose membrane (Schleicher and Schuell, Dassel,
Germany) using a minifold II vacuum filter device (Schleicher and Schuell, Dassel,
Germany). The membrane was baked at 80 ºC for 1 hr and incubated with 0.25 %
BSA/PBS containing streptavidin-conjugated horseradish peroxidase (BioGenex,
SanRamon, CA) at room temperature for 40 min with gentle shaking. The nitrocellulose
membrane was rinsed with washing buffer containing NaCl (0.26 M), EDTA (1 mM),
Tris-HCl (20 mM) and Tween 20 (1 %) for 1 hr at room temperature. ARP-labeled AP
sites were visualized by chemiluminescence (Amersham Corp, Piscataway, NJ) followed
by quantitative densitometry analysis using NIH ImageJ software.

4.2.3. Cell Growth Assay
HL60 and Jurkat cells were seeded in complete growth medium in a 6-well plate
5

(Falcon, Becton Dickinson) at a density of 5×10 cells per well. Cells were treated with
fludarabine or fludarabine plus MX and counted using a hemocytometer every 24 hr for 5
days.

4.2.4. Colony survival Assay
Tumor cells (2000/dish) were plated and treated with fludarabine (0-20 μM) or
fludarabine plus MX (3 mM) for 24 hrs. After treatment the drugs were removed, fresh
medium was added to the cells for 7 days. Survived colonies were stained with methylene
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blue for 30 min at room temperature and the colonies containing more than 50 cells were
counted to generate survival curves. To compare drug induced cytotoxicity DMF
parameter was calculated. DMF is defined as the ratio of the IC50 of fludarabine alone to
the IC50 obtained in the presence of the indicated modifier (DMF = IC50 for fludarabine
alone / IC50 for fludarabine plus MX). DMF indicates the degree of potentiation of
cytotoxicity by the modulator.

4.2.5.

Comet assay

The single cell comet electrophoresis assay was performed using Comet Assay kit
(Trevigen, Gaithersburg, MD). Approximately 5000 (in 50 µl) cells after exposure to
drugs were mixed with 250 µl of 1 % low melting point agarose in 1x PBS at 37 ºC. The
mixture (75 µl) was quickly pipetted onto a Comet slide (Trevigen, Gaithersburg, MD)
and allowed to solidify at 4 ºC. Slides were immersed for 30 min in prechilled lysis buffer
(2.5 mM sodium chloride, 100 mM EDTA pH 10, 10 mM Tris Base, 1 % sodium lauryl
sarcosinate, 0.01 % Triton X-100) at 4 ºC. After lyses, slides were incubated for 20 min in
alkali solution (0.3 M NaOH, 1 mM EDTA) at room temperature to allow unwinding of
DNA and then subjected to both neutral and alkaline electrophoresis for the next 30 min.
Comet in an individual cell was visualized by staining with Comet silver staining kit
(Trevigen, Gaithersburg, MD). Fifty cells per treatment were analyzed using NIH ImageJ
software to generate quantitative and statistical data. Cellular DNA damage was
expressed as the tail “length” and the “tail moment” that combines a measurement of the
length of the DNA migration and the relative DNA content therein (26, 35).
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4.2.6.

Western blot analysis

Cellular protein content was quantified spectrophotometrically using the Bio-Rad
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry
milk in TBST for 40 min at room temperature the blots were incubated with primary
antibody for 1 hour at room temperature. Sources of primary antibody were as follows:
APE, FEN1, PCNA, polymerase β, TDG (Santa Cruz Biotechnology, CA), UDG, MPG,
MBD4 (Abcam, Cambridge, MA), cleaved PARP (BD Pharmingen, San Jose, CA),
γH2AX (Bethyl, Montgomery, Texas), α-Tubulin (Sigma-Aldrich, St Louis, MO), Ogg1
(Novus Biological, Littleton, CO). The primary antibody solutions were prepared in 1 %
non-fat dry milk in TBST as followed: cleaved PARP 1: 1000 v/v dilution, APE 1:2000
v/v dilution, Fen1 1:200 v/v dilution, polymerase β 1:200 v/v dilution, UDG 1:500 v/v
dilution, PCNA 1:200 v/v dilution, TDG 1:200 v/v dilution, MPG 1:500 v/v dilution,
MBD4 1:500 v/v dilution, γH2AX 1:1000 v/v dilution, Ogg1 1:500 v/v dilution and
Tubulin 1:500 v/v dilution. Blots were incubated with HRP-conjugated secondary
antibody at room temperature for 1 hour. The blots were visualized by ECL (Amersham
Corp, Piscataway, NJ) according to the manufacturer instructions.

4.2.7.

RT-PCR assay

Total RNA was isolated from ~5 x 106 cells using RNAqueous-4PCR kit
(Ambion, Austin, TX) according with the manufacturer’s instructions. The extracted
RNA was quantitated by measuring absorbance at 260 nm using NanoDrop100
spectrophotometer (Thermo Scientific, Wilmington, Delaware). Then cDNA was
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synthesized from 5 μg of total RNA in a 20 μL reaction mixture according to the
manufacturer’s instructions using SuperScript III first strand kit (Invitrogen, Frederick,
Maryland) with random hexamers. The thermal profile of the reaction was set for stage 1:
10 min at 25 ºC; stage 2: 50 min at 50 ºC and stage 3: 5 min at 85 ºC. TaqMan MGB
probes (FAMTM dye labeled) for nuclear UDG (NM 080911.1) and β-actin
(NM001101.2) were used. To amplify the cDNA, 0.25 μg of the reversed transcribed
cDNA from cells were subjected to 40 cycles of PCR using TaqMan one-step RT-PCR
master mixture reagent kit in a 96-well optical plate. The cycling parameters in an ABI
7500 Fast Real-Time PCR System (Applied Biosystem, Foster City, CA) were as
follows: stage 1: 50 ºC for 2 min; stage 2: AmpliTaq activation 95 ºC for 10 min; stage 3:
40 cycles of amplification at 95 ºC for 15 s and stage 4: 60 ºC for 1 min. The amount of
target was calculated after normalization to the β-actin as an endogenous control.

4.2.8.

Immunofluorescence microscopy

Cells were grown on a 6 well plate and were treated with fludarabine and
fludarabine plus methoxyamine for 24 and 48 hrs. At each time point, cells were washed
with PBS and cytospin on a slide at 600 g for 8 min. Both treated and untreated cells
were fixed in 2 % paraformaldehyde and permeabilized with 0.2 % Triton X-100. Cells
were incubated with primary UDG antibody (Abcam, Cambridge, MA) for 1 hr at room
temperature, followed by secondary antibody conjugated with Alexa 488 (green)
(Molecular Probes, Carlsband, CA). Nucleus was stained using Hoersch dye, 2 mg/ml,
for 30 min at room temperature. Images were digitally captured using an Olympus
microscope equipped with a digital camera.
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4.2.9.

Xenograft tumors in nude mice

HL60, U937 and SW480 tumor cells (5 x 106) were injected into bilateral flanks
of female athymic nude mice (6 weeks old). The tumors were measured with calipers and
the tumor volume was calculated using the formula: V = L x I2 / 2, where V= tumor
volume (mm3), L is the largest diameter and I is the smallest diameter. When the tumor
volumes reached 100-150 mm3, mice were divided in control and treatment groups (6-9
mice/group).
Nude mice carrying tumors were treated with fludarabine alone (15 mg/kg), MX
(2 mg/kg) alone and the combination of the two agents, by daily intraperitonial injection
(i.p.) for 5 consecutive days. Tumor measurements were taken every 2 days. Tumor
responses were quantified by tumor growth delay. Tumor growth delays were calculated
using the formula: T2x – C2x, where T2x= the days to double tumor in size in drug treated
tumor, C2x= the days to double tumor in size in untreated tumor. Toxicity of the treatment
was evaluated by measuring the body weight three times weekly from the first day of
treatment until 2 weeks after the last treatment and also by analysis of whole blood counts
(days 1, 5, 10 and 15 after treatment).

4.2.10.

Statistical analyses

All results were expressed as mean ± SE. Statistical tests were performed using
InStat3.06 (GraphPad). P < 0.05 was considered statistically significant.

4.3. Results
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4.3.1.

The formation of abasic sites of arabinosyl nucleotides (ara-AP site) in

cells after exposure to fludarabine alone and in combination with MX
Studies in vitro and ex vivo using oligonucleotide demonstrated that F-ara-A
residues in DNA were recognized and removed by UDG (presented in chapter 3).
However, it is not clear whether the BER process of fludarabine occurs in cells. Thus, to
detect the formation of ara-AP sites in cells after exposure to fludarabine is like
confirming the initial step of BER in process of incorporated fludarabine in DNA. We
have measured AP sites in cells induced by alkylating agents (24) using an aldehyde
reactive probe reagent (ARP). ARP has been demonstrated to have similar chemical
structures to MX that can specifically bind to an aldehyde group in an AP site of the
natural deoxyribosyl sugar (23, 24). However, we do not know whether the AP site of an
arabinosyl sugar can be detected by ARP in cells. Therefore, in this study, ARP was the
first time used to measure ara-AP sites induced by fludarabine. Results showed that dose
and time dependent formation of ara-AP sites were detected in three cancer cell lines,
HL60, Jurkat and SW480 after fludarabine treatments (Figure 4-2. A & B) and that cotreatment with MX reduced detectable ara-AP sites. This reduction of ara-AP sites is
presumably due to the binding of MX to the aldehyde group of the ara-AP site to form a
MX-bound AP-site (24), making the ara-AP site unavailable for ARP. Importantly, these
results indicate that MX is capable of blocking the repair of incorporated fludarabine. The
ara-AP site assay was also performed in DLD1/UDG+/+ and DLD1/UDG-/-cells after
fludarabine treatments. While the formation of ara-AP sites induced by fludarabine
displayed a dose dependent effect in UDG+/+ cells, no increased ara-AP sites were
detected in UDG-/- cells (Figure 4-3. A) after exposure to increasing doses of fludarabine.
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Thus, no detectable ara-AP sites in UDG-deficient cells were the results of the lack of
UDG activity to recognize and remove incorporated F-ara-A, confirming that the activity
of UDG plays the role in the initial repair-process of fludarabine in cells. Additionally,
when genomic DNA extracted from these cells was incubated in vitro with purified UDG
enzyme and then label with ARP, no significant increase in ara-AP sites formation was
measured in UDG+/+ cells. In contrast, considerable increase in ara-AP sites was detected
in UDG-/- (Figure 4-3. B & C).
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Figure 4-2
Fludarabine induces formation of ara-AP sites that are bound by MX
A, The dose-dependent relationship between the levels of ara-AP sites and the
concentrations of fludarabine. The ara-AP sites in DNA were measured using ARP
reagent after HL60, Jurkat and SW480 cells were treated with fludarabine alone (0-20
μM) or in combination with MX (3 mM) for 24 hrs (* P<0.05 compared to fludarabine
alone). B, The time-dependent relationship between the numbers of ara-AP sites and the
length of time of exposure to fludarabine. The ara-AP sites were measured in Jurkat,
HL60 and SW480 cells treated with fludarabine alone (5 μM) or fludarabine plus MX (3
mM) for 12, 24, 48 and 72 hr (* P<0.05 compared to fludarabine alone). Results
represent the mean value of data from three independent experiments.
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Figure 4-3
Fludarabine induces formation of ara-AP sites in UDG wild-type cells but not in
UDG-/- cells
A, Comparison of the formation of ara-AP sites in colon cancer cells DLD1/UDG+/+
versus DLD1/UDG-/- cells after exposure to fludarabine. DLD1/UDG+/+ and DLD1/UDG/-

cells were treated with fludarabine (0-40 μM) for 24 hrs. DNA was extracted and ara-

AP sites were measured using ARP. B, The formation of ara-AP sites in DLD1/UDG+/+
cells after exposure to fludarabine (0-40 μM) for 24 hrs. DNA was extracted and divided
in two samples. In one sample, ara-AP sites in 10 μg of DNA were measured using ARP.
In the other sample, 10 μg of DNA were incubated with 5U of purified E. Coli UDG, for
2 hrs at 37 °C and subsequent ara-AP sites formed were labeled with ARP. C, Ara-AP
sites in DLD1/UDG-/- cells with or without incubation with purified UDG.
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4.3.2.

Up-regulation of cellular BER proteins after drug-treatments

In order to characterize the involvement of BER proteins in process of DNA
damage induced by fludarabine alone or in combination with MX, we next evaluated the
expression of BER proteins including UDG, APE, FEN1 and pol β in Jurkat and HL-60
cells before and after drug treatment. The altered expression of BER proteins displayed a
similar pattern in response to the drug treatment in these two cell lines. UDG, FEN1 and
pol β were up-regulated in varying degrees after exposure to either fludarabine alone or in
combination with MX. As shown in Figure 4-4. A, a significant induction of UDG was
seen in cells treated with the combination of fludarabine and MX when compared with
cells treated with fludarabine alone (3 folds increase based on densitometric analysis)
and the up-regulated UDG protein remained over a period of 72 hrs. It was noted that
UDG was slightly induced by MX alone at 72 hr after treatment in these two cell lines. It
is likely that the binding of MX to endogenous AP sites may stimulate UDG expression.
APE expression remained unchanged before and after drug treatment in cells, indicating
that either MX as a chemical compound or a MX-bond AP-site as a type of DNA damage
has no direct effect on APE (24, 25) and thus are not accompanied by the upregulation of
expression of this enzyme. APE can no longer recognize MX-bound AP site as a
substrate, leading to further inhibition of BER process. The expressions of several other
glycosylases, such as MPG, MBD4, TDG, AAG and Ogg1 were measured. No
significant changes were observed in the expression levels of these glycosylases (Figure
4-4. B). These results, together with one obtained from the enzymatic activity assay (no
cleavage activity observed, Chapter 3), suggest that the above mentioned glycosylase are
not involved in the recognition and removal of incorporated fludarabine.
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Moreover, to characterize the UNG gene transcript before and after the treatment with
fludarabine alone and fludarabine plus MX, a real time RT-PCR assay was used. The
values obtained for the target gene using TaqMan MGB probes were normalized to βactin values (endogenous control) for each sample. As shown in Figure 4-4. C, a 2 fold
increase in UNG transcript levels was observed for each time point, after fludarabine plus
MX treatments. Similar up-regulation in the protein expression levels was measured
using western blot analysis as described above, suggesting that MX-bound AP-sites may
be able to trigger UNG transcription and translation, to overcome the repair inhibition.
Furthermore, using immunofluorescence staining with UDG specific antibody, we
confirm the up-regulation of UDG expression levels as well as nuclear localization of the
protein after treatments with combined agents (Figure 4-4.D).
Although it is not clear yet for the exact mechanisms of induction of BER
proteins, the results suggest that the expression of these BER proteins are up-regulated in
response to the DNA damage formed by fludarabine and the combination of two drugs. It
is apparent that up-regulation of UDG indicates the involvement of this DNA glycosylase
in removing incorporated fludarabine as an aberrant base. Elevated poly β and FEN1 may
suggest that MX-AP sites stall short patch BER process and simultaneously activate long
patch BER, leading to upregulation of the key enzymes to pass through this blockage of
repair pathway.
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Figure 4-4
Induction of expression of some BER proteins and UNG mRNA levels
A, HL60 and Jurkat cells were continuously treated with drugs (5 μM fludarabine alone
and fludarabine plus 3 mM MX) and collected at 24, 48 and 72 hrs. Cell lysates were
subjected to western blot analysis with UDG, APE, FEN1, polymerase β, PCNA and
tubulin specific antibodies. Control (lane 1), fludarabine alone (lanes 2,4,6), fludarabine
plus MX lanes (3,5,7), MX alone (lane 8). B, No changes in the expression levels of other
glycosylase before or after treatment of Jurkat cells with fludarabine and fludarabine plus
MX. Cell lysates were subjected to western blot analysis with MPG, MBD4, Aag, TDG,
OGG1 and tubulin specific antibodies. C, Folds increased relative to control of the UNG
mRNA expression levels in Jurkat cells. D, Induction and localization of UDG in nucleus
after treatment with fludarabine (5 μM) plus MX (3 mM) for 24 and 48 hrs. Cells were
stained with UDG antibodies (green) and Hoersch dye (blue).
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4.3.3.

MX enhances fludarabine-induced DNA strand breaks

Previous data showed that the combination of MX and alkylating agents, BCNU
or TMZ, increased DNA strand breaks, leading to cell death (25, 26, 30, 36).

To

determine the induction of DNA damage induced by fludarabine alone or in combination
with MX, the comet assay was introduced. Comet assay has been shown to be a sensitive
and reliable measure of DNA strand breaks, AP sites, and incomplete excision repair
sites. Comet images of Jurkat cells are presented in Figure 4-5. A. DNA damage in a
single cell was assayed by both alkaline and neutral electrophoresis to detect single and
double strand breaks, respectively. After treatment of Jurkat cells with fludarabine (0-20
µM) plus MX (3 mM) for 4 hrs, distinct comets were observed compared to fludarabine
alone. Tail length determined by neutral comet assay (the appropriate parameter to
quantitate DNA damage for this condition, as indicated by manufacturer’s guidelines) was
~3-fold higher in cells treated with the combination of fludarabine and MX than that
produced by fludarabine alone, P< 0.05 (Figure 4-5. B). The increased DNA double
strand breaks were also observed with the duration of exposure to the combination of
fludarabine (5 µM) and MX (3 mM). In contrast, tail moment determined by alkaline
comet assay that measures DNA single strand breaks showed less differences in cells
between the treatments with fludarabine alone and the combination in both dose and time
dependent assays (Figure 4-5. C). Similar enhancement of fludarabine induced DNA
strand breaks by MX was also observed in other three cancer cell lines, including HL60,
U937 and SW480 (data not shown).
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Figure 4-5
MX enhances single and double strand breaks in
lymphoma cells treated with fludarabine
A, Comet images assayed by neutral and alkaline electrophoresis. Jurkat cells were
treated with fludarabine alone (5 μM) or fludarabine plus MX (3 mM) for 4 hrs. B,
Tail length of the comet detected by neutral electrophoresis in Jurkat cells after
treatments with fludarabine alone (0-20 μM) and fludarabine plus MX (3 mM) and
Tail length of comet detected by neutral electrophoresis at different times (4-24 hrs)
after Jurkat cells treated with 5 μM fludarabine or fludarabine plus 3 mM MX (*
P<0.05, compared with the treatment with fludarabine alone). C, Tail moment of the
comet detected by alkaline electrophoresis in Jurkat cells with the same treatments as
described in B. Results represent the mean values of data from three independent
experiments.
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4.3.4.

MX potentiates anti-tumor effect of fludarabine in vitro

To correlate DNA damage such as ara-AP sites and DNA strand breaks with the
killing effect induced by the drug treatments, cell death was assayed. The potential of
survival and cell growth were examined in cells treated with fludarabine in absence or
presence of MX. Considering the fact that therapeutic efficacy of alkylating agents
enhanced by MX was extensively studied in human colon tumor models, to establish the
therapeutic strategy that allows for comparison between the combination of MX with
alkylating agents and fludarabine, SW480 and RKO cells was selected and treated with
fludarabine alone and the combination with MX. Clonogenic Survival assayed in SW480
cells (Figure 4-6. A) revealed that MX enhanced fludarabine-cytotoxicity, showing that
the IC50 values for fludarabine was reduced from 13 μM to 6 μM by MX (DMF = 2.5,
p<0.05). RKO cells were more sensitive to fludarabine alone (IC50 = 8 µM). Co-treatment
with 3 mM MX sensitized cells to fludarabine with a dose modification factor (DMF) of 2
for RKO. HL60 and Jurkat cells were treated with fludarabine (5 µM) or fludarabine plus
MX (3 mM) and the viable cells were counted using tryptan blue exclusion every 24 hrs
for 5 days. Marked differences in cell growth were observed between the treatment of
fludarabine in absence or presence of MX (Figure 4-6. B). At day 5, ~ 50 % HL60 cells
and ~ 60 % of Jurkat cells remain viable after fludarabine alone, in contrast, the
combining fludarabine and MX significantly decreased the survival of cells; only 13.3 %
in HL60 and 24 % in Jurkat cells survived. The augment of cytotoxicity of fludarabine by
MX in these leukemia cells was also about 2.5 – 3.0 folds (p<0.02).
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Figure 4-6
MX potentiates therapeutic effect of fludarabine in tumors cells
A. Comparison of the cytotoxicity induced by fludarabine alone (0-20 μM) and the
combination of fludarabine and MX (3 mM) in tumors cells assayed by clonogenic
formation assay (SW480, RKO). B, Myeloid leukemia cells (HL60) and C, Lymphoma
cells (Jurkat) were treated with 5 μM fludarabine and fludarabine plus 3 mM MX and cell
viability was determined by tryptan blue exclusion. Cell viability is expressed as
percentage of untreated control (growth inhibition assay).
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4.3.5.

MX potentiates anti-tumor effect of fludarabine in vivo.

The therapeutic efficacy of this combination was further evaluated in xenografts of
HL60, U937 and SW480 cells in nude mice. When the tumor volumes reached 100-150
mm3 mice were divided into control and treatment groups (6-9 mice/group). Mice
received a single i.p. daily injection of fludarabine alone (15 mg/kg), MX (2 mg/kg) alone
or the combination of the two drugs (fludarabine 15 mg/kg and MX 2 mg/kg), for 5
consecutive days. Tumor responses were determined by tumor growth delay. As shown in
Figure 4-7 , a moderate sensitivity to fludarabine was observed in both xenografts, but
combined treatment significantly reduced tumor growth. HL60 xenograft treated with
PBS for 17 days had a mean tumor volume of 2500 106 mm3 compared with a mean
tumor volume of 1456 76 mm3 and 643±142 mm3 (P< 0.05) in mice treated with
fludarabine alone or in combination with MX, respectively. Similarly, MX enhanced the
tumor inhibitory effect of fludarabine was observed in U973 and SW480 xenografts. The
tumor growth delays were 11±0.6 days for HL60, 9±1.1 days for U973 and 10± 0.9 for
SW480 (P< 0.05). At these doses, mice did not present any evidence of toxicity, evaluated
by measurements of the body weight and whole blood toxicity analysis.
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Figure 4-7
MX potentiates therapeutic effect of fludarabine in human xenografts
Methoxyamine enhanced antitumor effect of fludarabine in human xenografts (HL60,
U937 and SW480). * P<0.05 compared with the treatment with fludarabine alone.
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4.4.

Discussion

We demonstrated that (i) the incorporation of fludarabine is processed by BER
mechanism, resulting in formation of ara-AP sites (ii) MX-blocked repair of ara-AP-sites
produced by fludarabine increases cell death through the blockage of BER, identifying a
new mechanism for fludarabine; (iii) MX potentiates the therapeutic efficacy of
fludarabine, developing a novel therapeutic strategy to combine inhibitor of BER with
fludarabine for clinical treatment.
Incorporation of fludarabine into DNA initiates the process of BER. As presented in
Chapter 3 by using oligonucleotide substrates containing F-ara-A residues, in vitro and ex
vivo UDG excised incorporated F-ara-A from DNA. This enzymatic action by UDG will
probably result in formation of an ara-AP-site in the DNA. Therefore, AP sites in DNA,
as the intermediates generated during base excision repair of abnormal bases, are the
indicators of activated BER pathway. In this study we demonstrated that ara-AP site
formation is proportional with fludarabine dose and time-exposure, indicating that
incorporated fludarabine is substrate of BER. This was further supported by studies
demonstrating that a fludarabine dose dependent formation of ara-AP sites was detected
in cells expressing UDG but not in their counterparts, in which expression of UDG has
been genetically turned off through UNG gene knockout. When genomic DNA of these
UNG-/- cells treated with fludarabine was in vitro reacted with purified UDG, a significant
increase in AP sites was measured. These results provide further evidence of the role of
UDG as well as the involvement of BER in processing incorporated fludarabine in cell.
However, we can not rule out the possibility of other glycosylases that may also have the
activity excising F-ara-A from DNA in cells, considering the fact that several DNA N-
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glycosylases have been identified in mammalian cells and that each excises a specific
damaged base with high specificity but allows some overlapping substrates (37).
MX binds to ara-AP sites to block BER. BER is the most pro-active repair pathway that
corrects DNA modifications arisen either spontaneously or from attack by reactive
chemicals and anticancer agents. BER is an essential repair pathway to maintain genome
stability and normal development, and is quantitatively an important mechanism of DNA
repair, by which drug resistance to variety of agents occurs. Thus, balanced expression of
BER proteins is crucial for a proper repair activity.
MX has been developed as a blocker of BER to potentiate cytotoxicity of
alkylating therapeutic agents such as TMZ and BCNU (24-27, 30). The action of MX to
block BER pathway is through the binding of an aldehyde group in an AP site, the
tautomeric open-ring form of deoxyribose. This biochemical reaction converts a
repairable AP-site into MX-bound AP-site. This DNA lesion is refractory to the lyase
activity of APE and poly β, consequently blocking the BER pathway. Our results
presented in Figure 4-2. confirmed the role of MX in binding to ara-AP sites formed by
fludarabine and the ability of MX-bound AP-sites to block repair of APE. Another
important validation link of the involvement of BER in response to the DNA damage
induced by the therapeutic treatment with fludarabine alone or in combination with MX
was the findings of induction of several BER proteins, including UDG, poly β and FEN1
in cells. UDG was significantly up-regulated after drug treatments, especially in cells
treated with combination of fludarabine and MX. Based on the observation that UDG has
a higher affinity for the products of AP-site than the actual substrate itself (44), it has been
proposed that subsequent to base release, UDG remains quickly rebound to the AP site to
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protect the cell until the AP site was conveyed to APE and poly β, the next enzymes in the
BER-pathway. Thus one possible explanation for induction of UDG by fludarabine and
MX is that the persistence of MX-bound AP-sites results in the accumulation of UDG at
un-repairable MX-bound AP-sites. DNA poly β is known to be the polymerase of choice
and limiting factor for the short patch BER due to its dual enzymatic activity, and FEN1
recognizes and cleaves the single stranded DNA ‘flap’ structures during the long patch
repair process. Thus, the elevated poly β and FEN1 suggest that MX-bound ara-AP-sites
impact on both short and long patch BER (18). Although the mechanisms of regulation of
BER proteins by the drug treatments are not clear yet, results suggest that BER proteins
have an adaptive response to DNA damage that is exaggerated by the combination of
fludarabine and MX. One possibility would be that the unrepaired damage, MX-bound
AP-sites is recognized by protective proteins such as Akt which will lead to activation of
several transcription factors. Another possible mechanism is again mediated by MXbound AP sites that can not be further process by BER which will lead to increase
transcription of the proteins involved in the repair process.
Lethal DNA lesions induced by the combination of fludarabine and MX contribute
to cell death. Combining fludarabine with MX indeed increased lethal cytotoxicity in
comparison with fludarabine alone. The combination produced higher levels of DNA
strand breaks and more cell death that were related to the persistence of MX-bound APsites. We have previously demonstrated that MX-bound AP-sites are stable DNA lesions
that can stall DNA synthesis, showing S phase arrest in cells after treatments. Cellular
responses to the replication stalling by the combination of MX and alkylating agent such
as TMZ (24) were accompanied by varying amounts of interphase nuclear DNA breaks
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and associated metaphase chromosomal aberrations (i. e., chromosome fragmentation and
sister chromatin exchange events). We have also reported that MX-bound AP-site acts as
a topo II poison to trap topo II in DNA cleavage complex, resulting in topo II mediated
DNA strand breaks and apoptosis (31). Thus, MX-bound AP-sites lethally cause cell
death in many ways.
Although fludarabine is widely used to treat hematological malignancies, the
therapeutic effect has been limited by several factors. For example, the major cytotoxic
effect of fludarabine appears to be specific to replicating cells, which may result in less
effective of fludarabine in indolent diseases because these tumor cells are usually
quiescent (10,42). Fludarabine can induce cell cycle arrest and apoptosis that is thought to
act primarily through the activation of p53. However, p53 is the most commonly mutated
tumor suppressor gene in human cancer. Tumor cells carrying an inactivating mutation of
p53 have been reported to be resistant to fludarabine (43, 44). Thus, MX enhancedtherapeutic efficacy of fludarabine by blocking BER should be promising with merits to
overcome these resistant factors. Obviously, blocking BER induced cytotoxicity is non
cell cycle specific, because BER mechanism is active throughout the entire cell cycle.
Therefore, the potentiation of fludarabine by MX can be expected to be effective on both
proliferating and resting tumor cells. Importantly, we demonstrated that MX enhanced
fludarabine cytotoxicity in HL60 and Jurkat cells. These two cell lines are p53 deficient
and Jurkat has the defect in function of mismatch repair (MMR). Thus, the potentiation by
MX is independent of p53 and MMR status, which agrees with our previous observations
(24, 26).
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Implications of cancer treatment. The studies presented here suggest a viable
synergistic approach for enhancing fludarabine cancer therapy involving disruption of
base excision repair. Targeting BER-based therapeutic strategy can be extended to the
combination of MX with any drugs that produce abnormal bases to incorporate into DNA
either through acting as the nucleotide analogs or manipulating the nucleotide pools.
Overall, this therapeutic strategy could improve both therapeutic index by decreasing the
dose of anticancer drugs and therapeutic efficacy for the treatment of hematological
malignancies.
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CHAPTER V
MITOCHONDRIAL MEDIATED CELL DEATH INDUCED BY
FLUDARABINE COMBINED WITH METHOXYAMINE DUE TO
BLOCKAGE OF BASE EXCISION REPAIR PATHWAY

Abstract
Nuclear and mitochondrial DNA are constantly being exposed to damaging agents
from endogenous and exogenous sources. To ensure viability of cells, elaborate
mechanisms of DNA repair are essential for both nuclear and mitochondrial DNA
(mtDNA). We have previously shown that base excision repair (BER) is activated by the
fludarabine induced DNA damage. Methoxyamine (MX), an inhibitor of BER is able to
enhance fludarabine cytotoxicity in cancer cell lines and human xenografts. The process
of mitochondrial BER (mtBER) is very similar to that in nuclei, thus we hypothesize that
mtDNA is also a target for fludarabine and MX and may represent an important aspect of
cell death. We have demonstrated that dose dependent fludarabine treatments resulted in
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proportional formation of mitochondrial AP sites, which are formed after the first step in
mitochondrial BER. These mtAP-sites were efficiently bound by MX. MX-bound APsites may become stable DNA lesions that have the potential to interrupt mtBER
mechanism, leading to apoptotic cell death. These events were accompanied by a
concomitant increase cleavage of PARP and caspase 9, loss of mitochondrial membrane
potential (JC-1 staining) and integrity and enhanced expression levels of proapoptotic
mitochondrial proteins (e.g., Bax.). Together, our findings suggest a mitochondrial
mediated apoptotic death after fludarabine and MX treatments.

5.1

Introduction
Many of the effective chemotherapeutic agents such as nucleoside analogues have

mechanisms of action that target DNA. The ability of tumor cells to tolerate DNA
damage and maintain their viability after treatments may contribute to reduce the
desirable, cytotoxic outcome. Therefore, elucidating the mechanism that sense and repair
DNA damage and targeting this mechanism is essential for development of more
effective therapeutic strategies.
Fludarabine, an adenosine analogue, is effective in the treatment of the
hematological malignancies such as chronic lymphocytic leukemia and non-Hodgkin’s
lymphoma (1, 2). Fludarabine is a potent inhibitor of DNA synthesis through the actions
of its triphosphate metabolite, F-ara-ATP (3-8). F-ara-ATP incorporates into replicating
strand causing reduced DNA synthesis. We have previously reported that a major DNA
repair pathway, base excision repair, is involved in the cell response to fludarabine
treatments, through the enzymatic activity of uracil-DNA glycosylase (9). Furthermore,
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we have shown that methoxyamine (MX), a known inhibitor of BER, enhanced antitumor
effect of fludarabine in vitro and in human tumor xenografts. MX binds to arabinosyl
(ara)-AP sites formed by fludarabine and turn the repairable DNA damage into lethal
lesion, leading to cell death. However, the molecular mechanism by which cells are killed
by the combined treatment, fludarabine and MX is largely unknown.
Apoptosis, the most common form of cell death, is known to occur via an
extrinsic (death receptor-ligand) or intrinsic (mitochondrial-centered) pathway (10). The
apoptotic cascade is characterized by the activation of cysteine proteases called caspases,
which cleave proteins essential for the survival of the cell. These caspases activate the
endonucleases responsible for the internucleosomal cleavage of genomic DNA (11).
Mitochondria play a key role in the events leading to caspases activation in cell
undergoing apoptosis (12). Cell death at the mitochondrial level is initiated by alteration
of the mitochondrial membrane which induce release of cytochrome c in cytosol where
forms a complex with Apaf1 (apoptotic protease activating factor-1), ATP and inactive
initiator procaspase-9, called the apoptosome (13-15). This complex is sufficient to
recruit and activate caspase-9. Once activated, caspases-9 cleaves the downstream
caspases (16,17). Death initiated by mitochondria is regulated by members of the Bcl-2
family (18).
In our studies, we note that treatments with fludarabine and MX resulted in a
significant percentage of cells that undergo apoptosis. We propose that mitochondrial
DNA (mtDNA) may also be an important target for fludarabine and MX, in addition to
the conventional target, nuclear DNA (9) and together, these two DNA damage signals
contribute to induction of mitochondrial mediated apoptosis.
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Mt DNAs, 16.5 kb circular DNA molecules, have their own DNA repair systems
(19). Mitochondrial BER (mtBER) pathway is very similar to the nuclear pathway and
includes four distinct steps: lesion removal by a glycosylase, AP sites processing by an
AP-endonuclease, insertion of a new nucleotide by polymerase γ and ligation by a DNA
ligase (20-25). Thus, we propose that mtBER may be activated in response to fludarabine
induced mtDNA damage. If MX binds mtAP-sites and thereby blocks the BER pathway
in mitochondria, the level of damage induced by fludarabine will eventually become
severe leading to lost of mitochondria ability to maintain their membrane potential and
then activate apoptotic death pathway.

5.1.1. Hypothesis and Rationale
Research focus: To delineate the contribution of mitochondrial apoptotic pathway
in cell death after fludarabine and MX exposure.
We hypothesized that cell death induced by fludarabine and MX is increased due
to apoptotic signals emanating from mitochondrial DNA damage (Figure 5-1.).
We have examined whether fludarabine targets mtDNA and whether fludarabine
is a substrate for mitochondrial BER. We also evaluated if MX is able to bind
mitochondrial AP sites, thus blocking the repair pathway. Fludarabine and MX
treatments resulted in a mitochondrial mediated apoptotic death.
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Figure 5-1
Working model: mitochondrial BER response to Fludarabine-induced DNA damage
which triggers mitochondrial mediated apoptotic cell death
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5.2.
5.2.1.

Materials and Methods
Cells and reagents

Human tumor cell lines, Jurkat (lymphoblastic) and HL60 (myelocitic leukemic)
used in these studies were obtained from the American Type Culture Collection
(Rockville, MD) and cultured in proper mediums. Fludarabine was obtained from Berlex
Laboratories (Richmond, CA) and freshly prepared with mediums (containing alkaline
phosphatase) for the treatment. Methoxyamine (MX) was purchased from Sigma
Chemical Co (St. Louis, MO). MX was dissolved in sterilized water (pH 7.0) and stock
solution (2.5 M) was stored at -20 ºC.

5.2.2.

Extraction of mitochondrial DNA

Mitochondrial DNA isolation was carried out as described previously (23) with
some modifications. After treatments, cells were harvested and washed with PBS. The
cell pellet was resuspended in 10 mM Tris- 10 mM EDTA buffer; 10 % SDS solution
was added and incubated at room temperature for 10 min. RNase A was added for 15 min
at 37 °C followed by incubation with Proteinase K for 15 min at 37 °C. 5 M NaCl was
added to precipitate the high molecular DNA, overnight at 4 °C. The cell lysate was
centrifuged at 12,000 rpms for 30 min at 4 °C. The supernatant was transferred to a new
tube and the remaining cell lysate was centrifuged again for 10 min at same speed. The
supernatants were combined and mtDNA was extracted once with phenol: chlorophorm
(1:1 v/v) and 1:1 v/v to above lysate supernatants. The mixture was centrifuged at 6000
rpms for 10 min. The aqueous phase was transferred to a new tube and mtDNA was
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precipitated by adding 2 x volume of cold 100 % ethanol. The mtDNA was washed once
and resuspended in water.

5.2.3.

AP site assay

The AP sites were measured using ARP (aldehyde reactive probe) reagent. ARP
and MX have the same chemical reactivity; they competitively bind to an aldehyde group
at an AP site. Therefore, ARP only detects MX-free AP sites. The assay was performed
as previously described with minor modifications (26-29). Briefly, cells (2x106) were
plated and exposed to fludarabine (0-20 µM) with or without MX (3 mM). Cells were
collected at 24 hr after treatment and dose-dependent AP sites were measured. After
extraction, mtDNA (10 μg) was incubated with 15 µl of 1 mM ARP (Dojindo
Laboratories, Kumamoto, Japan) in 150 µl PBS solution at 37 ºC for 15 min. DNA was
then precipitated with 400 µl ice-cold ethanol (100 %) at -20 ºC for 20 min and washed
with 70 % ethanol. MtDNA was dried at room temperature for 30 min and then
resuspended in TE buffer to achieve a final concentration of 0.3 μg/100 µl. The ARPlabeled mtDNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on ice and
mixed with an equal amount of 2 M ammonium acetate. The DNA was then immobilized
on BA-S 85 nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) using a
minifold II vacuum filter device (Schleicher and Schuell, Dassel, Germany). The
membrane was baked at 80 ºC for 1 hr and incubated with 0.25 % BSA/PBS containing
streptavidin-conjugated horseradish peroxidase (BioGenex, SanRamon, CA) at room
temperature for 40 min with gentle shaking. ARP-labeled mtAP sites were visualized by
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chemiluminescence (Amersham Corp, Piscataway, NJ) followed by quantitative
densitometry using NIH ImageJ software.

5.2.4.

Detection of mitochondrial DNA damage using PCR analysis

Amplification products were obtained by PCR of purified mitochondrial DNA.
Primers pairs that target human mitochondrial genome were L-primer (5' 15740

CTTTATTGACTCCTAGCCGCAGAC
CTGGTCAACCTCAACCTAGGCC

3611

–

3’)

and

H-primer

(5’-

15717
3590

-3’), which yield a product of 4467 bp (Figure

4-2 A). Template primers, 5 μL of 10 x buffer (without MgCl2) and dH2O were mixed in
a 0.2 ml thin-walled PCR tube and heated for 5 min at 99.9 °C. The mixture was
immediately placed on ice, at which time the remaining reagents were added. The final
concentrations in the 50 μL amplification cocktail were 1x PCR buffer (Invitrogen), 300
nM each primers, 1.5 mM MgCl2, 200 μM each dNTP and 2.6 U of Taq DNA
polymerase. The PCR cycling profile used was: a pre-PCR incubation at 94 °C for 2 min,
then 25 cycles of 94 °C for 15 sec, 50 °C for 30 sec and 68 °C for 4 min and then to 4 °C
using the PCR system. Controls for the PCR were performed by amplification of GAPDH
gene. The primers used for GAPDH were the following: GAPDH sense 5’
GAGGGGCCATCCACAGTCTTCTG

3’

and

GAPDH

antisense

5’

CCCTTCATTGACCTCAACTACATGGT 3’ (Sigma Genosys, Woodlands, TX). The
PCR profile for the GAPDH gene amplification was the following: 24 cycles made up by
4 steps; 1: 4 min at 95 °C, 2: 55 s at 95 °C, 3: 55 s at 65 °C and 4: 30 s at 72 °C; followed
by 6 min at 72 °C. An aliquot of each reaction mixture after PCR, in 6x loading buffer,
was resolved by electrophoresis in TBE buffer at 90 V in a 0.5 % agarose gel.
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5.2.5.

Western blot analysis

Cellular protein content was quantified spectrophotometrically using the Bio-Rad
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry
milk in TBST for 40 min at room temperature, the blots were incubated with primary
antibody for 1 hour at room temperature. Sources of primary antibody were as follows:
Bcl2, Bax (Santa Cruz Biotechnology, CA), cleaved caspase 9 (Cell Signaling, Danvers,
MA), cleaved PARP (BD Pharmingen, San Jose, CA), γH2AX (Bethyl, Montgomery,
Texas), α-Tubulin (Sigma-Aldrich, St Louis, MO). The primary antibody solutions were
prepared in 1 % non-fat dry milk in TBST solution as followed: cleaved PARP 1: 1000
v/v dilution, Bcl2 1:200 v/v dilution, Bax 1:200 v/v dilution, cleaved caspases 9 1:500 v/v
dilution, γH2AX 1:1000 v/v dilution, and Tubulin 1:500 v/v dilution. Blots were
incubated with HRP-conjugated secondary antibody at room temperature for 1 hour. The
blots were visualized by ECL (Amersham Corp, Piscataway, NJ) according to the
manufacturer instructions.

5.2.6

Measurement of apoptosis by Annexin V staining

Cells were continuously treated with fludarabine (0-20 μM), MX (3 mM) or both
drugs in combination and collected after 24, 48 and 72 hrs drug exposure. After two
washes with PBS, cells were resuspended in 1 x binding buffer at a concentration of 1 x
106/mL. Cells were exposed at room temperature for 15 min to 5-μL Annexin V-FITC
(BD Bioscience, San Jose, CA) following the instructions of the manufacturer. Analysis
was carried out with FACSort (Becton Dickinson & Co., Mountain View, CA).

143

5.2.7.

Cytofluorometric analysis of mitochondrial transmembrane potential

(ΔΨm) by JC1
JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazoyl carbocyanine iodide,
Cell Technologies, Mountain View, Ca) is a lipophilic cationic dye that enters the inner
mitochondrial matrix in its monomeric form when the mitochondrial membrane is
polarized (Reers et al., 1991, 1995). Cells were treated with the indicated amounts of
drugs either alone or in combination for 24 hrs. Cells were then washed with 1 x assay
buffer and incubated for 15 min at 37 ºC with 1x JC1 reagent. In healthy cells the dye
stains the mitochondria bright red. In the apoptotic cells, the mitochondrial membrane
potential collapses and the JC1 reagent cannot accumulate within the mitochondria. In
these cells JC1 remains in the cytoplasm in a green fluorescent monomeric form. The red
form has absorption/emission maxima at 585/590 nm, while the green monomeric form
has absorption/emission maxima at 510/527 nm. Cells were analyzed on FACSCalibur
(Becton Dickinson, San Jose, CA) flow cytometer.

5.2.8.

Immunofluorescence microscopy

Cells were grown on a 6 wells plate and were treated with fludarabine and
fludarabine plus methoxyamine for 24 and 48 hrs. At each time point, cells were washed
with PBS and incubated with 250 nM MitoTracker (Molecular Probes, Carlsband. CA) at
37 °C for 45 min. Then, cells were washed twice with PBS and cytospin on a slide at 600
g, for 8 min. Both treated and untreated cells were fixed in 2 % paraformaldehyde and
permeabilized with 0.2 % Triton X-100. Cells were incubated with primary cytochrome
C antibody (Santa Cruz) for 1 hrs at room temp, followed by secondary antibody
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conjugated to Alexa 488 (green) (Molecular Probes, Carlsband, CA). Nuclei were stained
using Hoersch dye, 2 mg/ml, for 30 min at room temperature. Images were digitally
captured using an Olympus microscope equipped with a digital camera.

5.3.

Results

5.3.1.

Exposure to fludarabine alone and in combination with MX leads to
mtDNA damage

Previous studies have reported that one class of nucleotide transporter (hENT1) is
localized in the mitochondrial compartment (30). Several nucleotide analogues have been
shown to use hENT1 transporter to target mtDNA (31). However, it is not clear whether
fludarabine is actively transported into mitochondrial and subsequently induces mtDNA
damage. In these studies we employed a PCR based method to measure the mtDNA
damage after drug treatments. HL60 and Jurkat cells were treated with fludarabine alone
(0-80 μM) or fludarabine plus MX (3 mM) and harvested at 24 hr. Total DNA and
mtDNA was isolated and analyzed by PCR with primers that amplify a 4.4 kb segment of
mitochondrial genome (Figure 5-1. A) or GAPDH primers (for control). As Figure 5-2. B
shows, a substantial reduction in the 4.4-kb amplification product corresponding to the
mitochondrial genome was detected with DNA isolated from Jurkat cells treated with
increase concentration of H2O2. H2O2 is a known agent proved to induce extensive
mitochondrial DNA damage. We used this treatment as a positive control to validate our
method. We use GAPDH as a control for our PCR reactions.
When the same cells were treated with fludarabine for 24 hr, a decrease of 30 % in
amplification signal was observed at the highest concentration of fludarabine, while a
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more significant decrease in amplification was measured when cells were treated with the
combination of fludarabine and MX. A 30 % decrease was observed at 10 μM
fludarabine plus 3 mM MX which reached 54 % decrease at the concentration of 40 μM
(Figure 5-2. C). Similar results were obtained when HL60 were incubated with
fludarabine or fludarabine plus MX and assessed for mtDNA damage. Fludarabine alone,
at very high concentration (100 μM) resulted in a 50 % reduction in amplification signal,
while the same concentration of fludarabine plus 3 mM MX resulted in a very significant
decrease in the amplification rate (76 %) (Figure 5-2. D). These results prove that the
combination of fludarabine and MX targets mtDNA resulting in overall reduced
amplification suggesting the presence of mtDNA damage that cannot be overcome by the
polymerase employed in the PCR reaction.

146

Figure 5-2
Detection of mitochondrial DNA damage induced in the presence of fludarabine
plus MX
A,

The length and localization of the PCR amplification product in the human

mitochondrial genome B, PCR amplification products were resolved in 0.5 % agarose gel
and visualized by ethidium bromide staining. A representative picture shows a reduction
in the 4.4 kb product corresponding to the mitochondrial genome. Amplification was
done with DNA from Jurkat cells incubated with H2O2 (0-800 μM) for 1 hr and collected
24 hr after treatment. Amplification of the GAPDH served as a control for the PCR. C,
Jurkat cells were treated with fludarabine (0-80 μM) or fludarabine plus 3 mM MX for 24
hr and mtDNA damage was measured. Vertical bars measure relative amplification based
on the density of the bands that is inversely proportional to the extent of DNA damage D,
HL60 cells were treated with fludarabine (0-100 μM) or fludarabine plus 3 mM MX for
24 hr and mtDNA damage was measured.

147

A
4467 bp PCR product

B
Jurkat
M

H2 O2 (0-800μM)

mtDNA Target
GAPDH

C

Fludarabine
Fludarabine + MX

100
90

Fludara (0-40μM)

80

% amplification

Jurkat
Fludara (0-40μM) +MX H2 O

mtDNA Target

70
60
50
40
30
20

GAPDH

10
0

0

10

20

40

D

HL60
100

H2 O
Fludara (0-100μM) +MX

mtDNA Target
GAPDH

90

% amplification

Fludara (0-100μM)

Fludarabine
Fludarabine + MX

80
70
60
50
40
30
20
10
0
0

148

10

20

40

80

100

5.3.2.

Formation of ara-AP sites in mitochondrial DNA after exposure to

fludarabine alone and in combination with MX
The above experiments confirm that the combination of fludarabine and MX
targets mtDNA and determines mtDNA damage. Our previous studies showed that the
MX enhancement of fludarabine-induced nuclear damage is due to binding of MX to the
ara-AP sites formed by fludarabine and subsequent interrupts BER pathway. Considering
that fludarabine action is mediated by the incorporation of the nucleotide analog into
DNA strand, we hypothesize that fludarabine is incorporated into mtDNA and
mitochondrial (mt) BER pathway is activated. Therefore, a direct assay was used to
measure the mtBER response after fludarabine, by measuring mitochondrial ara-AP sites
using ARP. ARP has been demonstrated to have similar chemical structures to MX and
can specifically bind to an aldehyde group in an AP site (27, 32). Tumor cells were
treated with fludarabine alone (0-20 μM) or fludarabine plus MX (3 mM) and harvested
at 24 hr. MtDNA was extracted and mtAP-sites were measured. Results showed
formation of that mtAP-sites proportional with fludarabine concentrations, in the two
cancer cell lines used HL60 and Jurkat (Figure 5-3. A & B). Co-treatment with 3 mM
MX reduced by 2-4 folds the detectable mtAP-sites (Figure 5-3. A & B). This reduction
of mtAP-sites is presumably due to the binding of MX to the aldehyde group of the
mtAP-sites to form MX-bound AP-sites, making the mtAP-sites unavailable for ARP.
Importantly, these results indicate that MX is capable of blocking mitochondrial repair of
fludarabine-induced damage. These results are also in agreement with our PCR analysis
results of mtDNA damage which showed increased damaged when cells were treated
with the combination of the two drugs.
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Figure 5-3
Fludarabine induces formation of mitochondrial ara-AP sites that are bound by MX
A, The dose-dependent relationship between the levels of mtAP-sites and the
concentrations of fludarabine. The ara-AP sites in mtDNA were measured using ARP
reagent after Jurkat cells were treated with fludarabine alone (0-20 μM) or in combination
with MX (3 mM) for 24 hrs (* P<0.05 compared to fludarabine alone). B, The dosedependent relationship between the levels of mtAP-sites and the concentrations of
fludarabine (0-20 μM) or fludarabine plus MX (3 mM) for 24 hr in HL60 (* P<0.05
compared to fludarabine alone). Results represent the mean value of data from three
independent experiments.
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5.3.3.

MX enhances fludarabine induced apoptosis

To correlate mtDNA damage such MX-bound mtAP-sites with the killing effect
induced by the drug treatments, apoptotic cell death was assayed. HL60 and Jurkat cells
were treated with fludarabine (5 µM) in the absence and presence of MX (3 mM) and
collected at 24, 48 and 72 hr after treatments. Each sample was subjected to analysis of
apoptosis by stained with Annexin V and detection of expression levels of apoptotic
proteins by western blotting assay. The results showed that fludarabine alone produced
low percentage of apoptotic cells in HL60 and Jurkat cell lines (Figure 5-4. A) and cotreatment of fludarabine with MX significantly increased Annexin V-positive cells. At 72
hr the combination-treatment induced 60-70 % of cells undergoing to apoptosis, which
was 3 to 7-fold higher than that induced by fludarabine alone in HL60 and Jurkat cells
respectively. We next examined proteolytic cleavage of PARP by caspases, which is a
hallmark of apoptosis. As shown in Figure 5-4. B, time-dependent PARP cleavage was
seen in HL60 and Jurkat cells after drug treatment. In HL60 cells, cleaved PARP was
detected by 48 and 72 hr of treatments with either fludarabine alone or in combination
with MX. In Jurkat cells, cleaved PARP was significantly induced by the combination of
fludarabine and MX. The enhanced PARP cleavage appeared to continue to accumulate
even as late as 72 hr, suggesting that this process of caspase activation was more
specifically activated by the combination treatment in Jurkat cells. Moreover, γH2AX,
the marker of DNA strand break, was also remarkably induced by the combined
treatment in both cell lines, which was consistent with the cleaved PARP, suggesting that
DNA strand breaks produced by the combination of fludarabine and MX may signal for
cell death. Further, we monitored the expression of several apoptotic proteins after
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fludarabine alone or combined treatments (Figure 5-4 B) in a time dependent fashion.
Treatment of HL60 and Jurkat cells with MX, fludarabine alone, or in combination,
exerted little effect on expression of Bcl2, an antiapoptotic protein. In contrast, the levels
of proapoptotic protein Bax were induced. In HL60 cells, at 24 and 72 hr, there was a
slightly induction of Bax by fludarabine or the combination. A peak level in Bax
expression was observed at 48 hr after combined treatments. Similarly, expression levels
of Bax were up-regulated after treatment of Jurkat cells with fludarabine plus MX
starting at 24 hr and persisted over 72 hr. Finally, the expression levels of
procaspase/caspases 9, an important mitochondrial related apoptotic protein were
determined. Treatments of HL60 cells with fludarabine alone resulted in minimal
cleavage/ activation of procaspase 9 at 24 and 48 hr and a slightly increased effect at 72
hr. However, the exposure of cells to fludarabine and MX resulted in marked induction of
caspases activation. In Jurkat cells, more modest effects are measured even after the
exposure of cells to combined treatments.
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Figure 5-4
MX potentiates fludarabine induced mitochondrial mediated apoptotic cell death
A, The percentage of Annexin V-positive cells produced by fludarabine alone and
fludarabine plus MX at 24, 48 and 72 hr (*P<0.05 compared with the treatment with
fludarabine alone). B, Induction of the cleaved form of PARP, γH2AX, Bcl-2, Bax and
caspases 9 proteins was detected by western blotting in cells after treatments with
fludarabine alone and in combination with MX. Control (lane 1), fludarabine alone (lanes
2,4,6), fludarabine plus MX (lanes 3,5,7), MX alone (lane 8). Results are representative
of at least three experiments.
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5.3.4.

Loss of mitochondrial membrane potential as a result of mitochondrial

DNA damage induced by combined treatment
Induction of apoptosis, particularly by cytotoxic drugs, is intimately related to
mitochondrial dysfunction [33]. Consequently, the effects of combined exposure to
fludarabine and MX on mitochondrial integrity were examined. Mitochondrial membrane
potential is a key indicator of cellular viability, as it reflects the pumping of hydrogen
ions across the inner membrane during the process of electron transport and oxidative
phosphorylation, the driving force behind ATP production (Figure. 5-5 A). The lipophilic
mitochondrial probe JC-1 was used to estimate changes in membrane potential (Δψm).
Cells were treated with fludarabine and fludarabine plus MX for 24, 48 and 72 hr. At
each time point, JC-1 reagent was added and cells were analyzed by flow cytometry for
polymeric (intramitochondrial) and monomeric (cytosolic) forms of JC-1. As shown in
Figure 5-5. B exposure to fludarabine had minimally affected the transmembrane
potential. In contrast, combined exposure MX/fludarabine resulted in a 6-fold increase in
the fluorescence intensity for the monomeric form of the dye at 24 hr. This significant
increase in the percentage of cells that lost their mitochondrial membrane potential after
combined treatments lasted over 72 hr (Figure 5-5 C).
These results are consistent with the preceding measurements of apoptotic cells and they
indicate that exposure of leukemic cells to fludarabine and MX results in a marked
potentiation of mitochondrial dysfunction and activation of apoptotic pathway.
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Figure 5-5
Fludarabine plus MX induced mitochondrial membrane potential collapse
A, mtDNA damage can lead to decrease in electron transport and subsequent to loss of
mitochondrial membrane potential. B, An example of the flow cytometer data for the
drug-induced loss of mitochondrial membrane potential in Jurkat cells as determined with
JC-1 dye. The polymeric form (intramitochondrial) is found in the top quadrant while the
monomeric form of the dye (cytosolic) is found in the bottom quadrant. C, Jurkat cells
were treated with 5 μM fludarabine or fludarabine plus 3 mM MX for 24, 48 and 72 hr.
The percentage of cells that lost their mitochondrial membrane potential was determined
using JC-1 staining and flow cytometer as described in B.
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5.3.5.

Loss of mitochondrial integrity induced by combined treatment

Parallel studies were carried out using Jurkat cells treated fludarabine or
fludarabine plus MX which at 24 hr after treatment were cytospin on a slide and
immunofluorescence stained for mitochondria with MitoTracker (MT) and cytochrome
C. In the control cells, cytochrome C and MT co-localized in the mitochondria (Figure 56). After treatments with either fludarabine or MX alone, no visible effect was observed,
which correlated with previous published data [34]. However, when cell were treated
with 5 μM fludarabine plus 3 mM MX for 24 hr, both cytochrome C and MT
fluorescence signals were reduced and accompanied by disruption of the arranged
organization of mitochondria in cytoplasm. These data are in agreement with our
mitochondrial membrane potential data. The combination of fludarabine plus MX
induces mtDNA damage presumably through the inhibition of mtBER that will
eventually lead to loss of mitochondrial membrane potential and mitochondrial collapse.
As an end point, mitochondrial-mediated apoptosis will be triggered.
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Figure 5-6
Immunocytochemistry of mitochondrial damaged caused by fludarabine plus MX
treatments
Jurkat cells were treated with indicated drugs for 24 hr. Cells were stained for
mitochondria with MitoTracker (red) for 30 min , pelleted on a slide at 600 g for 8 min,
fixed in 2 % paraformaldehyde, and stained for cytochrome C (green) with monoclonal
antibody (Santa Cruz) and secondary antibody Alexa 488. DNA was visualized with
Hoersch (blue). The very right panel represents the composed images.
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5.4.

Discussion
In addition to the nuclear genome, cells harbor a mitochondrial genome.

Mitochondrial DNA exists as a 16.6 kb circular structure and contains 13 oxidative
phosphorylation genes, two rRNAs, and 22 tRNAs. The increased susceptibility of the
mtDNA to drug-induced damage, as compared with the nDNA, has been previously
documented (35); however, the specific molecular causes of these phenomena are not
well understood. It has been hypothesized that a combination of biological determinants,
such as the proximity of the mtDNA to ROS, the lack of a compact nucleosome structure
to protect the genome, and a paucity of mtDNA damage-processing pathways relative to
those present in the nucleus play a role (36). Moreover, the susceptibility of mtDNA and
the role of mitochondrial repair pathways to the damage induced by specific class of
chemotherapeutic agents such as nucleotide analogs have been poorly investigated.
Previous data (chapter 3 and chapter 4) have shown that fludarabine-induced
nuclear DNA damage activates BER. Combining fludarabine with MX, an agent that
blocks BER, led to significant cell death. In the present study we prove that mtDNA is a
site for fludarabine and MX actions and we elucidated the mechanism of cell death
induced by the combination of the two agents along with the role of mitochondria in this
process.
Mitochondrial BER system is activated as response to fludarabine damage. It has
been shown that several types of mtDNA damage are repaired by a short-patch mtBER
process (21). Here, we report for the first time that fludarabine and fludarabine combined
with MX induced mtDNA damage. At low fludarabine concentration, the global
assessment of mtDNA damage using PCR amplification showed minimal effects. In

162

contrast, when fludarabine was combined with MX, low amplification was measured,
suggesting the presence of significant mtDNA damage. Also, we considered measuring a
more specific type of mtDNA damage and that was the mtAP-site formation. Our results
showed for the first time that fludarabine induces formation of mtAP-sites which are
bound by MX resulting in inhibition of further mtBER. These MX-bound AP-sites
refractory to BER will result in global mtDNA damage.
Interruption of BER by MX results in induction of mitochondrial mediated
apoptosis. Measurements of apoptotic cell death revealed that the combination of
fludarabine plus MX resulted in more than additive apoptotic cell death. To determine the
prevalence of intrinsic (mitochondrial-mediated) over extrinsic (death receptor) pathway
in execution of apoptotic cell death, several approaches were used.
(i) Time course analyses of mitochondrial membrane potential in whole cells
demonstrated that fludarabine alone had minimal effect on mitochondrial integrity, as
previously reported (37). In contrast, fludarabine plus MX treatments lead to a significant
percentage of cells that lost their mitochondrial membrane potential. To explain this
observation, we propose that mitochondrial MX-bound AP–sites block mtBER leading to
accumulation of mtDNA damage. Accumulation of unrepaired mtDNA damage will
eventually become severe, impairing the electron transport machinery along the inner
membrane that will lead to collapse of the mitochondrial membrane potential.
(ii) Immunofluorescence microscopy using Mitotracker, a mitochondrial staining, and
cytochrome c antibody were conducted. The immunofluorescence images confirmed these
results, showing a disrupted arrangement of mitochondria.
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(iii) These events were accompanied by cleavage and activation of PARP and caspase 9.
Also, the expression levels of proapoptotic protein Bax are up-regulated, suggesting that
Bax is translocated to the outer mitochondrial membrane. Bax translocation to the
mitochondria has been shown to reduce mitochondrial membrane potential, enhance
cytochrome c release from mitochondria and activate caspases (37).
Together, our results point out for the first time that the combination of fludarabine and
MX targets mtDNA. Interruption of mtBER pathway along with nuclear BER induces
severe damage, leading to lost of mitochondria ability to maintain the membrane potential
and subsequent activation of mitochondrial mediated apoptotic death.
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CHAPTER VI
DISRUPTION OF BASE EXCISION REPAIR BY METHOXYAMINE
SENSITIZIES CHRONIC LYMPHOCYTIC LEUKEMIA CELLS TO
FLUDARABINE

Abstract
We have applied our findings on biochemical mechanisms governing fludarabineinduced cytotoxic effects (Chapter 3-5) to test if fludarabine plus MX combination can
improve the treatment of chronic lymphocytic leukemia (CLL). More specifically, we are
investigating how blockage of the DNA base excision repair (BER) pathway via BER
inhibitor, methoxyamine affects the action of the nucleotide analog fludarabine. In this
study, we used primary CLL cells and similar experimental approach, as employed in
previous chapters. Enhancement of fludarabine toxicity by methoxyamine was analyzed
using in vitro assays, including AP sites assay, Comet assay to quantitate DNA damage,
apoptosis via Annexin staining, mitochondrial membrane potential via JC1 staining and
Western Blotting and RT-PCR analysis for protein expressions and transcript levels of
key BER enzymes as well as apoptotic proteins. Data showed that activity of fludarabine
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was effectively modulated by methoxyamine in CLL cells. Enhancement of fludarabineinduced cytotoxicity was dependent on formation of nuclear and mitochondrial ara-AP
sites by fludarabine which are bound by MX. Primary CLL lymphocytes exhibited
intrinsically higher BER expression and activity when compared with normal
lymphocytes. CLL cells were significantly more sensitive to the fludarabine in
combination with methoxyamine as assayed by cytotoxicity, apoptosis, and levels of
DNA damage. Exposure of CLL lymphocytes to fludarabine plus MX treatments resulted
in mitochondrial-mediated apoptosis with loss of mitochondrial membrane potential and
enhanced cytosolic release of proapoptotic mitochondrial proteins.
This study shows that through manipulation of the BER pathway, an increase in response
to fludarabine is achieved in CLL lymphocytes. Thus, the combination of fludarabine
plus methoxyamine has potential for further clinical targeted therapy, with lower toxicity
to normal cells.

6.1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of lymphoid
malignancies with a variable clinical course (1). It is manifested by progressive
accumulation of morphological mature but immunological dysfunctional B lymphocytes.
Outcome for advanced-stage CLL patient is poor, with an expected median survival of
three years (2). Although the introduction of purine nucleoside analogues (3) and
monoclonal antibody therapies such as alemtuzumab and rituximab (4,5), either as single
or in combination regimens (6), have led to improved significant response rates, none of
these options are curative. Consequently, there is a need for novel therapeutic strategies in
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the treatment of CLL.
Fludarabine is a synthetic adenine nucleoside analog approved as the first-line
treatment in CLL. Fludarabine is used, as a stand-alone drug, as well as in combination
with chemotherapeutic agents such as cyclophosphamide (7,8), cytararabine (9,10) or
cisplatin (11,12). While it has been shown to be effective in inducing complete remission,
many patients eventually develop drug resistance leading to disease progression.
Fludarabine is an inhibitor of DNA synthesis through the actions of its triphosphate
metabolite, F-ara-ATP (13-19). F-ara-ATP incorporates into replicating strand causing
reduced DNA synthesis. Although the relative contributions of diverse molecular actions
of fludarabine to cell death remain unknown, its incorporation in the DNA strand appears
to be required for lethality (20). We have previously shown that incorporated F-ara-A
acts as an abnormal base in DNA and initiates base excision repair (BER) through the
enzymatic activity of uracil DNA glycosylase (21), using tumor cell lines (Chapter 3,
Chapter 4).
BER is initiated by a DNA glycosylase that recognizes and removes the
inappropriate base with the formation of a potentially cytotoxic abasic (AP) site that is
processed by an AP endonuclease (APE). APE incises the phosphodiester backbone
immediate at the 5’ position to the lesion, leaving behind a strand break. Replacement of
the damaged base and religation of the DNA involves recruitment of DNA polymerase β
and ligase III (22-27). BER is the most efficient repair mechanism to repair a variety of
base lesions, contributing to cells resistance to anticancer agents that produce DNA
lesions. Thus, expression and activity of BER key proteins in CLL lymphocytes may play
a role in development of resistance to fludarabine treatments. It also may be an important
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factor for the development of new combinatory therapeutic strategy to target BER, with
high selectivity toward tumors cells by exploiting the biological differences between
normal and cancer cells. Methoxyamine (MX), an inhibitor of BER, specifically binds to
AP sites (28-39) preventing their processing by APE and leading to accumulation of
these cytotoxic sites in DNA. Recently, we have shown that MX improves the therapeutic
efficacy of fludarabine in vitro and in human tumor xenografts (21). Exploring the
combination of fludarabine and MX in the treatment of CLL is a first step toward
developing future targeted combinatory treatment regimens.
An important feature of CLL cells that contributes to failure of the treatments is
their resistance to apoptosis due to several factors such as Bcl2 overexpression or
increase production of anti-apoptotic cytokines (40). Apoptosis, the most common form
of cell death, is known to occur via an extrinsic (death receptor-ligand) or intrinsic
(mitochondrial-centered) pathway, in which mitochondria play a key role in the events
leading to caspase activation. Mitochondrial DNA is a target for damage induced by a
variety of therapeutic agents (41-43). Even though mitochondrial DNA (mtDNA) lacks
efficient repair systems, a simplified BER pathway have been established that is similar
with the one in nuclei (42). Thus, in addition to nuclear DNA (the conventional target of
fludarabine) mtDNA may also be targeted and perhaps an important mediator of
apoptosis during mtBER disruption by MX in CLL lymphocytes.
The present work was designed to show for the first time that MX enhances
fludarabine cytotoxicity in CLL. We studied the intrinsic BER expression and activity of
CLL lymphocytes and the response to fludarabine and MX treatments. We quantified araAP site formation, monitored expression levels of relevant proteins and measured
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production of DNA strand breaks after combined treatments. We also characterized the
nature of the cell death induced in CLL by fludarabine and MX combination. Our data
showed that fludarabine treatment has generated dose- and time-dependent formation of
nuclear and mitochondrial ara-AP sites in CLL cells which were bound by MX. MXbound AP-sites were resistant to BER and eventually led to enhanced single and double
DNA strand breaks triggering mitochondrial mediated apoptosis. Taken together, these
results established for the first time the basis for a possible clinical therapeutic strategy.

6.2.

Materials and Methods
6.2.1. Reagents and enzymes
Fludarabine was obtained from Berlex Laboratories (Richmond, CA) and freshly

prepared when used. Methoxyamine was purchased from Sigma Chemical CO (St. Louis,
MO), dissolved in sterilized water (pH 7.0) at a concentration of 2.5 M (stock solution)
and stored at -20 ºC. E. Coli Uracil DNA glycosylase (UDG) and human AP
endonuclease (APE) were purchased from Trevigen (Gaithersburg, MD).

6.2.2. Isolation and culture of primary cells
Peripheral blood was obtained from CLL patients and healthy donors who have
provided written informed consent. The clinical characteristics of the patient cohort is
summarized in Table 5-I. Heparinized peripheral blood samples were fractioned by
Ficoll-Paques sedimentation (Sigma Chemicals, St Louis, MO). Freshly isolated
peripheral blood lymphocytes were cultured in RPMI medium (HyClone, Logan, Utah)
supplemented with 10 % fetal bovine serum and 1 % L-Glutamine at a density of 1 x
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106/ml. Lymphocytes were incubated at 37 ºC in a humidified 5 % carbon dioxide
atmosphere in the presence of fludarabine (0-20 μM), MX (3 mM) or both drugs in
combination. In addition, control cultures with no drug added were carried out. All
experiments were performed in duplicates.
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Tabel 6-I. Characteristics of the 47 patients

CLL patients

Normal donor

Male

15

9

Female

18

6

Median

58

41

Range

44 - 78

30-67

Median

69 x 103// μL

8 x 103// μL

Range

11 – 365 x 103// μL

5- 11 x 103// μL

Characteristics
Sex

Age (years)

Lymphocytes counts (per μl)
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6.2.3. DNA glycosylase/APE assay
The fluorescent HEX labeled 40-mer oligonucleotide containing a deoxyuridine
residue at position 19 and its complement strand labeled with Cy5 were synthesized by
Operon Biotechnologies (Huntsville, Alabama). The sequences of the top and bottom
strands were: 5’[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGG
GG (top) and 5’-[Cy5]CCCCGGGTACCGAGCTCGAATGCACTGGCCGTCGTTTT
AC (bottom). Duplex oligonucleotides were generated by annealing the two
complementary strands in a reaction buffer containing 10 mM Tris-HCl, 50 mM KCl, and
1 mm EDTA, by incubation at 95 ºC for 5 min followed by slow cooling at room
temperature for 1 hour. The standard assay mixture for DNA glycosylase activity,
containing 4 pmols of the fluorescent labeled duplex oligonucleotides in 20 µL buffer [1
mM EDTA, 1 mM dithiothreitol (DTT), and 20 mM Tris-HCl (pH 8.0)] was incubated
with purified DNA glycosylase (UDG) for 1 hr at 37 ºC. The reaction was stopped at 95
°C for 5 min. After excising the misincorporated base by DNA glycosylase, abasic sites
were incised by 1 unit of purified APE at 37 °C for 1 hr. Similar procedure was used to
measure glycosylase activity of cell extracts. Substrate was incubated with cell extracts
for 30 min, at 37 °C. The reaction was stopped at 95 °C. Ten ml of loading buffer (300
mmol/L NaOH, 97 % formamide and 0.2 % bromophenol blue) were added and reaction
mixtures were heated to 95 ºC for 5 min, then cooled at 4 ºC on ice. Reaction products
were resolved by electrophoresis through denaturing 19 % polyacrylamide gels (7 M
urea, 1x Tris-borate-EDTA) and visualized by using a Typhoon 9200 fluorescent Imager
(Amersham BioScience, Piscarawat, NJ). Fluorescent densities were quantified using
ImageQuant software.
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6.2.4.

AP site assay

The AP sites were measured using ARP (aldehyde reactive probe) reagent that
reacts with an aldehyde group at an AP sites. MX binds to the AP site at the same
aldehyde group. Therefore, the ARP reagent only detects MX-free AP sites. The assay
was performed as previously described (34, 44-46) with minor modifications. Briefly,
cells (2x106) were plated and exposed to fludarabine (0-20 µM) with or without MX (3
mM). Cells were collected at 24 hrs after treatment and dose-dependent AP sites were
measured. Alternatively, for the time-dependent assay, cells were exposed to 5 µM
fludarabine with or without MX (3 mM) up to 72 hrs. Cells were harvested at 12, 24, 48
and 72 hrs, respectively. After extraction with phenol (Fischer Scientific, Fair Lawn, NJ)
and chloroform (Sigma-Aldrich, St Louis, MO), DNA (10 g) was incubated with 15 µL
of 1 mM ARP (Dojindo Laboratories, Kumamoto, Japan) in 150 µL PBS solution at 37
ºC for 15 min. DNA was then overnight precipitated with 400 µL ice-cold ethanol (100
%) at -20 ºC and washed with 70 % ethanol. DNA was dried at room temperature for 30
min and then resuspended in TE buffer to achieve a final concentration of 0.3 g/100 µL.
The ARP-labeled DNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on
ice and mixed with an equal amount of 2 M ammonium acetate. The DNA was then
immobilized on BAS 85 nitrocellulose membrane (Schleicher and Schuell, Dassel,
Germany) using a minifold II vacuum filter device (Schleicher and Schuell, Dassel,
Germany). The membrane was baked at 80 ºC for 1 hr and incubated with 0.25 %
BSA/PBS containing streptavidin-conjugated horseradish peroxidase (BioGenex,
SanRamon, CA) at room temperature for 40 min with gentle shaking. The nitrocellulose
membrane was rinsed with washing buffer containing NaCl (0.26 M), EDTA (1 mM),
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Tris-HCl (20 mM) and Tween 20 (1 %) for 1 hr at room temperature. ARP-labeled AP
sites were visualized by chemiluminescence (Amersham Corp, Piscataway, NJ) followed
by quantitative densitometry analysis using NIH ImageJ software.

6.2.5.

Western blot analysis

Cellular protein content was quantified spectrophotometrically using the Bio-Rad
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry
milk in TBST for 40 min at room temperature the blots were incubated with primary
antibody for 1 hr at room temperature. Sources of primary antibody were as follows:
cleaved PARP (BD Pharmingen, San Jose, CA), APE, Fen1, polymerase β, PCNA (Santa
Cruz Biotechnology, CA), UDG (Abcam, Cambridge, MA), cleaved caspase 9, Bax,
Bcl2, topoisomerase IIα (Cell Signaling, Danvers, MA), and Tubulin (Sigma-Aldrich, St
Louis, MO). The primary antibody solutions were prepared in 1 % non-fat dry milk in
TBST as followed: cleaved PARP 1: 1000 v/v dilution, APE 1:2000 v/v dilution, Fen1
1:200 v/v dilution, polymerase β 1:200 v/v dilution, UDG 1:500 v/v dilution, PCNA
1:200 v/v dilution, Bcl2 1:200 v/v dilution, Bax 1:200 v/v dilution, cleaved caspases 9
1:500 v/v dilution, γH2AX 1:1000 v/v dilution, topoisomerase IIα 1:500 v/v dilution and
Tubulin 1:500 v/v dilution. Blots were incubated with horseradish peroxidase-conjugated
secondary antibody (1:1000 v/v dilutions in 1 % non-fat dry milk in TBST) for 1 hr. The
blots were visualized by ECL (Amersham Corp, Piscataway, NJ) according with the
manufacturer’s instructions.
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6.2.6.

RT-PCR assay

Total RNA was isolated from ~5 x 106 lymphocytes using RNAqueous-4PCR kit
(Ambion, Austin, TX) according with the manufacturer’s instructions. The extracted
RNA was quantitated by measuring absorbance at 260 nm using NanoDrop100
spectrophotometer (Thermo Scientific, Wilmington, Delaware). Then cDNA was
synthesized from 5 μg of total RNA in a 20 μL reaction mixture according to the
manufacturer’s instructions using SuperScript III first strand kit (Invitrogen, Frederick,
Maryland) with random hexamers. The thermal profile of the reaction was set for stage 1:
10 min at 25 ºC; stage 2: 50 min at 50 ºC and stage 3: 5 min at 85 ºC. TaqMan MGB
probes (FAMTM dye labeled) for nuclear UDG (NM 080911.1), topoisomerase IIα
(NM001067.2) and β-actin (NM001101.2) were used. To amplify the cDNA, 0.25 μg of
the reversed transcribed cDNA from cells were subjected to 40 cycles of PCR using
TaqMan one-step RT-PCR master mixture reagent kit in a 96-well optical plate. The
cycling parameters in an ABI 7500 Fast Real-Time PCR System (Applied Biosystem,
Foster City, CA) were as follows: stage 1: 50 ºC for 2 min; stage 2: AmpliTaq activation
95 ºC for 10 min; stage 3: 40 cycles of amplification at 95 ºC for 15 s and stage 4: 60 ºC
for 1 min. The amount of target was calculated after normalization to the β-actin as an
endogenous control.

6.2.7.

Measurement of Cell Growth

Lymphoma cells were seeded at a density of 5×105 cells/well in 6-well plates
in the presence of 10 % (v/v) fetal bovine serum. Cells were treated with various
concentrations of fludarabine (5-20 μM) or fludarabine plus MX (3 mM). Viable

181

cells were counted daily, for 5 days, in a hemocytometer (10 µL of cell suspension),
using tryptan blue exclusion.

6.2.8.

The alkaline and neutral single cell gel electrophoresis (Comet) assay

The single cell comet electrophoresis assay was performed using Comet Assay kit
(Trevigen, Gaithersburg, MD). Approximately 5000 (in 50 µL) cells after the treatment
were mixed with 250 µL of 1 % low melting point agarose in 1x PBS at 37 ºC. The
mixture (75 µL) was quickly pipetted onto a Comet slide (Trevigen, Gaithersburg, MD)
and allowed to solidify at 4 ºC. Slides were immersed for 30 min in prechilled lysis buffer
(2.5 mM sodium chloride, 100 mM EDTA pH 10, 10 mM Tris Base, 1 % sodium lauryl
sarcosinate, 0.01 % Triton X-100) at 4 ºC. After lysis, slides were incubated for 20 min in
alkali solution (0.3 M NaOH, 1 mM EDTA) at room temperature to allow unwinding of
DNA and then subjected to both neutral and alkaline electrophoresis for the next 20- 30
min. Comet in an individual cell was stained with Comet silver staining kit (Trevigen,
Gaithersburg, MD) and visualized using an online CCD camera. Fifty cells per treatment
were analyzed using NIH ImageJ software to generate quantitative and statistical data.
Cellular DNA damage was expressed as the “tail length” for neutral conditions and “tail
moment” that combines a measurement of the length of the DNA migration and the
relative DNA content therein, for the alkaline conditions (47).

6.2.9.

Measurement of apoptosis by Annexin V staining

Cells were continuously treated with fludarabine (0-20 μM), MX (3 mM) or both
drugs in combination At 24 hrs after exposure to drugs, cells were harvested by
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centrifugation. After two washes with PBS, cells were resuspended in 1 x binding buffer
at a concentration of 1 x 106/mL. Cells were exposed at room temperature for 15 min to
5-μL Annexin V-FITC (BD Bioscience, San Jose, CA) following the instructions of the
manufacturer. Analysis was carried out with FACSort (Becton Dickinson & Co.,
Mountain View, CA).

6.2.10. Cytofluorometric analysis of mitochondrial transmembrane potential
(ΔΨm) by JC1
JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazoyl carbocyanine iodide,
Cell Technologies, Mountain View, Ca) is a lipophilic cationic dye that enters the inner
mitochondrial matrix in its monomeric form when the mitochondrial membrane is
polarized (Reers et al., 1991, 1995). Cells were treated with the indicated amounts of
drugs either alone or in combination for 24 hrs. Cells were then washed with 1 x assay
buffer and incubated for 15 min at 37 ºC with 1x JC1 reagent. In healthy cells the dye
stains the mitochondria bright red. In the apoptotic cells, the mitochondrial membrane
potential collapses and the JC1 reagent cannot accumulate within the mitochondria. In
these cells JC1 remains in the cytoplasm in a green fluorescent monomeric form. The red
form has absorption/emission maxima at 585/590 nm, while the green monomeric form
has absorption/emission maxima at 510/527 nm. Cells were analyzed on FACSCalibur
(Becton Dickinson, San Jose, CA) flow cytometer.

6.3.

Results
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6.3.1.

Higher BER activity and proteins expression are intrinsic properties
of CLL

Based on our previous studies showing that BER pathway is involved in response
to fludarabine damage, we characterize the repair properties of CLL lymphocytes. The
repair capacity of human CLL lymphocytes was evaluated in comparison with the
activity of the normal lymphocytes or the activity of several types of human cancer cell
lines. The enzymatic activity was determined by incubation of a specific BER substrate
(synthetic 40 mer double-stranded oligonucleotide containing a deoxyuridine at the
position 19) with cell extracts from these cells. Each sample was also subjected to
western blot analysis and RT-PCR for protein expression and mRNA expression levels,
respectively. As shown in Figure 6-1. A, the cell extracts from three different
representative CLL samples had increased repair activity when compared with similar
cell extracts from normal lymphocytes. The repair enzymatic activity was measured by
incubation of the 40 mer double stranded oligonucleotide with 5 μg cell extracts for 30
min at 37 ºC, which resulted in a cleaved fragment visualized by 19 % polyacrylamide
denaturing gel. In contrast, when the enzymatic activity of CLL cell extracts was
evaluated in comparison with extracts from other human cancer cell lines (Figure 6-1. A),
similar levels were observed by in vitro enzymatic assays. Moreover, western blot
analysis for endogenous expression levels of UDG and APE, enzymes responsible for
enzymatic activity shown, were used to determine whether the increased enzymatic
activity correlates to increased protein expression. Untreated CLL or normal cells were
lysate and subjected for western blot analysis for UDG. The protein levels were
quantitated based on densitometric analysis and normalized to the β-actin levels. As
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shown in Figure 6-1. B, primary CLL cells exhibited a significant higher UDG
expression levels compared with normal lymphocytes. An example of the blots used in
these studies is also presented. Further analysis revealed that elevated UDG in CLL cells
was accompanied by less dramatic elevation in APE levels when compared with normal
cells (Figure 6-1. C). Additionally, we determined the basal expression levels of nuclear
transcript of UNG by RT-PCR analysis. As Figure 6-1. D shows, the transcript levels in
primary CLL samples were more heterogeneous, the majority of the samples expressed
higher levels of UNG transcripts, while few had lower expression when compared with
normal lymphocytes. Among the population of normal cells, the expression of the
transcripts was has uniform and low.
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Figure 6-1
Higher BER proteins expression levels and activity in CLL samples
A, Cleavage of BER substrate (40 mer double-stranded oligonucleotide containing a
deoxyuridine at the 19 position) by cell extracts from untreated CLL or normal donor
lymphocytes. 5’-end labeled 40 mer oligonucleotides were incubated for 30 min, at
37 ºC with 5 μg of several cell extracts. The products of reaction were analyzed by
electrophoresis on 19 % denaturating polyacrylamide gels. Comparison of BER
enzymatic activities of tumor cells, CLL and normal lymphocytes. The cleaved
products were obtained after oligonucleotide substrates were incubated with 5 μg cell
extracts. B, Same cell lysates were subjected to Western blot analysis with UDG and
APE specific antibodies. Elevated levels of both UDG and APE enzymes in
lymphocytes from CLL samples compared with lymphocytes from healthy donors. C,
Quantification of UDG and APE basal protein expression levels in CLL samples
versus normal samples. D, Quantification of UNG mRNA basal levels

in CLL

versus ND samples, using RT-PCR analysis. Representative of three independent
experiments.

186

A
Cell extract

-

+

+

+

+

+

+

UDG/APE

+

-

-

-

-

-

-

(5 µg)

Cell extract

-

UDG/APE

+

+
-

+

+

+

+

+

-

-

-

-

-

40 mer

40 mer

18 mer
SW480 HCT Jurkat HL60 ND CLL

B

C

90

ND

UDG

APE

Actin

Actin

CLL

80
70
60
50
40
30
20
10
0

CLL

ND

8

APE expression
normalized to B-actin

UDG expression
normalized to B-actin

18 mer

CLL

ND

7
6
5
4
3
2
1
CLL

D
UNG mRNA expression
normalized to B-actin

CLL

0

ND

5.5
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0

(5 µg)

CLL

187

ND

ND

6.3.2.

In fludarabine treatment of CLL lymphocytes, ara-AP sites are
formed following BER activation and are bound by MX.

The promising observed difference in repair activity between CLL and normal
lymphocytes led us to evaluate BER response in processing fludarabine residues by
measuring the formation of arabinosyl (ara)-AP sites in CLL lymphocytes after drug
treatments. We measured the ara-AP sites formed in cells using AP site assay based on
the capacity of the aldehyde reactive probe reagent (ARP) to bind to the aldehyde free
moiety of the AP site. Human lymphocytes were incubated with fludarabine in the
presence or absence of MX. Total genomic DNA was isolated, labeled with ARP and
analyzed. As shown in Figure 6-2. A, the number of ara-AP sites in DNA proportionally
increased with the concentration and with the duration of exposure to fludarabine (Figure
6-2. B). Co-treatment with MX reduced detectable ara-AP sites generated by fludarabine.
This reduction of ara-AP sites is presumably due to the binding of MX to the aldehyde
group of the ara-AP site to form a MX-bound AP-sites (31, 36), thereby making the araAP sites unavailable for ARP. These results demonstrate that lymphocyte exposure to
fludarabine initiates BER response.
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Figure 6-2
Fludarabine induces ara-AP sites formation due to the presence of active BER
pathway in CLL lymphocytes
A, The dose-dependent relationship between the numbers of ara-AP sites and the
concentrations of fludarabine. CLL lymphocytes were treated with fludarabine alone (020 μM) or fludarabine plus MX (3 mM) for 24 hrs. Genomic DNA was extracted and
ara-AP sites were measured using aldehyde reactive probe reagent (*, p<0.05). B, The
time-dependent relationship between the number of ara-AP sites and the time of
exposure to fludarabine. CLL lymphocytes were treated with fludarabine alone (5 μM) or
fludarabine plus MX (3 mM). Cells were collected at 24, 48 and 72 hrs treatments and
ara-AP sites were measured using ARP. Data represents the mean of at least triplicate
experiments.
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6.3.3.

BER proteins UDG and pol β are upregulated in CLL cells co-treated
with fludarabine and MX

To further characterize the involvement of BER in the process of DNA damage
induced by fludarabine or by the combination of fludarabine with MX, we subsequently
evaluated the expression of BER proteins: UDG, APE, FEN1, pol β and PCNA in
lymphocytes before and after drug treatment. UDG and pol β were up-regulated after
exposure to either fludarabine alone or the combination. Still, a more significant elevation
of these two proteins was observed in cells treated with fludarabine plus MX (Figure 6-3.
A) and their up-regulation persisted over a period of 72 hrs. In contrast, APE levels did
not change before and after drug treatment indicating that MX and MX-bond AP sites
have no direct effect on APE. To investigate whether the induction of UDG protein levels
is regulated at the transcriptional levels, a real time RT-PCR assay was used. CLL
lymphocytes were treated with fludarabine alone (10 μM) or fludarabine plus MX ( 3
mM) for 24 hr. The RNA was isolated, cDNA was prepared and analyzed using TagMan
MGB probes and RT-PCR amplification. The values obtained for the target gene were
normalized to β-actin values (endogenous control) for each sample. Results presented in
Figure 6-4 showed that at 24 hr, the UNG transcript levels were 2-3 folds increased after
exposure of cells to combined treatments, when compared to fludarabine alone. The
mechanism of BER proteins induction remains to be further elucidated; these results
indicate that the BER pathway is targeted and activated as an adaptive response to the
DNA damage formed by fludarabine and the combination in human CLL lymphocytes.
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Figure 6-3
Induction of protein and mRNA expression of BER related enzymes
as a response to fludarabine and MX combined treatment
CLL lymphocytes were continuously treated with fludarabine alone (5 µM) or
fludarabine plus MX (3 mM) and collected at 24, 48 and 72 hrs. Cell lysates were
subjected to Western blot analysis with UDG, polymerase β, APE1, Fen1, PCNA and
tubulin specific antibodies. C = control, F = Fludarabine alone, F + M = Fludarabine plus
MX; M = MX.
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Figure 6-4.
Induction of mRNA levels of nuclear isoform of UNG
A, CLL lymphocytes were continuously treated with fludarabine alone (10 µM) or
fludarabine plus MX (3 mM) and collected at 24 hr. The RNA was isolated; cDNA was
prepared and analyzed using TagMan MGB probes and RT-PCR amplification. The
values obtained for the target gene were normalized to β-actin values (endogenous
control) for each sample. UDG transcript level for each individual patient is presented. B,
Average values.
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6.3.4.

MX combined with fludarabine generates DNA strands breaks

We have shown previously that the combination of MX and fludarabine or
alkylating agents such as BCNU or TMZ, increased DNA strand breaks in cancer cell
lines, leading to cell death (31, 42-44). We used comet assay to asses the induction of
DNA strand breaks by fludarabine or the combination with MX in CLL lymphocytes.
DNA damage in a single cell was assayed by neutral electrophoresis to detect double
strand breaks and representative Comet images are shown in Figure 6-5. A. When
quiescent human lymphocytes were incubated for 24 hrs in the presence of various
concentrations of fludarabine plus 3 mM MX, a dose dependent increase in the tail length
was observed. In contrast, fludarabine alone at the same concentrations range (0-20 μM)
had no significant effect on comet formation and tail length. The levels of strand breaks
were evaluated by assessing tail lengths of at least 50 comets for each experimental
regimen. Results showed that MX enhanced 2-4 folds the tail length when combined with
fludarabine (Figure 6-5. B). In addition, time course treatments in the same experimental
conditions were used to determine the persistence or the repair of strand breaks after
either single agent (5 μM fludarabine, 3 mM MX) or combined treatments. As illustrated
in Figure 6-5. C, the DNA damage induced by 5 μM fludarabine was minimal over a 72
hrs period. However, when cells were treated with fludarabine combined with MX, the
comet tail length was significantly increased and it failed to recover (to control values)
over 72 hr which suggests that MX suppressed any repair process of the fludarabineinduced DNA damage.
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Figure 6-5
MX enhances fludarabine-induced DNA single and double strand breaks in CLL
A, Comet images, neutral conditions. CLL lymphocytes were treated continuously with
5-20 µM fludarabine and /or fludarabine plus 3 mM MX for 24 hrs. B, Tail length of the
comet formed in neutral electrophoresis after dose-dependent treatments with fludarabine
alone (0-20 μM) and fludarabine plus MX (3 mM) C, Tail length of comet formed after
continuously treatments with 5 µM fludarabine or fludarabine plus 3 mM MX for 24, 48
and 72 hrs. Data represent the mean of at least triplicate experiments, * p<0.05.
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6.3.5.

Induction of Topoisomerase IIα levels correlates with CLL sensitivity
to the combined treatments

One mechanism involved in the generation of double-strand breaks relies on the
formation of MX-bound ara-AP sites refractory to BER that can act as topoisomerase
poisons to stabilize the DNA-topoisomerase IIα cleavable complex. Thus, the
endogenous and drug-related topoisomerase IIα (topo II) levels were measured. We
compared the basal levels of protein expression and transcript in fresh CLL cells with that
of normal lymphocytes obtained from healthy donors. As shown in Figure 6-6 A, the
protein expression in all CLL lymphocytes was higher compared with normal cells.
Moreover, analysis of the topo II transcript levels by RT-PCR revealed that higher
protein expression is due to higher transcript levels, when compared with normal cells
(Figure 6-6. B). These results are in agreement with our previously published data that
there is a difference of 20 fold in topo II expression between primary cells and tumor cell
lines. Next, the drug-related induction of topo II at the levels of protein expression and
transcript were measured by Western Blot and RT-PCR analysis, respectively. As shown
in Figure 6-6. C, prolong induction of topo II was seen in CLL lymphocytes over a
period of 72 hr after exposure of cells with fludarabine plus MX, compared with
treatment with fludarabine alone. We then examined the relationship between induced
protein expression and the transcript levels in lymphocyte cells before and after drug
treatments. The total RNA was extracted from CLL lymphocytes treated with either
fludarabine alone or in combination with MX and topo II transcript levels were assayed
by RT-PCR analysis. Results showed a 2-3 fold increase in topo II transcript levels after
fludarabine plus MX treatments (Figure 6-7) in each sample tested.
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To correlate the DNA strand breaks accompanied by induction of topo II with the killing
effect determined by the drug treatments, cell death was assayed. Lymphocytes from
CLL were treated with 5 µM fludarabine or fludarabine plus 3 mM MX and cells were
counted every day using triptan blue exclusion. As shown in Figure 6-6. D, lymphocyte
cells were sensitive to the combination of fludarabine and MX, MX enhancing
fludarabine cytotoxicity by 2 fold.
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Figure 6-6
MX enhances fludarabine induced cell death in CLL due to induction of
Topoisomerase IIα levels
A, Comparison of the mRNA levels of topoisomerase IIα between human CLL
lymphocytes and human normal lymphocytes, assayed by RT-PCR. B, CLL lymphocytes
were continuously treated with fludarabine alone (5 µM) or fludarabine plus MX (3 mM)
and collected at 24, 48 and 72 hrs. Cell lysates were subjected to Western blot analysis
with topoisomerase IIα and tubulin specific antibodies. C = control, F = Fludarabine
alone, F + M = Fludarabine plus MX; M = MX. C, Comparison of the levels of
topoisomerase IIα between human CLL lymphocytes and human normal lymphocytes,
assayed by western bloting. Representative of three independent experiments. D, The CLL
lymphocytes were treated with fludarabine (5 µM) and fludarabine plus MX (3 mM). Cell
viability was determined by tryptan blue exclusion. Cell viability is expressed as
percentage of untreated control. (* p<0.05).
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Figure 6-7. The Topo II mRNA expression after treatments.
A, CLL lymphocytes were continuously treated with fludarabine alone (10 µM) or
fludarabine plus MX (3 mM) and collected at 24 hr. The RNA was isolated, cDNA was
prepared and analyzed using TagMan MGB probes and RT-PCR amplification. The
values obtained for the target gene were normalized to β-actin values (endogenous
control) for each sample. Topo IIα transcript level for each individual patient is
presented. B, Average values.

203

A
Topo II mRNA expressions after treatments
Folds increase relative to control

6
5
4
3
2
1
0

Fludara

Fludara+ MX

B

Folds increase relative to control

Average Topo II mRNA expression after treatments
6
5

(n=10)

4
3
2
1
0

Fludarabine

Fludarabine + MX

204

6.3.6.

MX blocks the repair of Fludarabine-induced mitochondrial DNA

damage and leads to mitochondrial mediated apoptosis
Since mitochondrial DNA (mtDNA) is potentially targeted by fludarabine, the
effects of fludarabine alone and the combination with MX were determined at the levels
of mtDNA. CLL lymphocytes were exposed to increased fludarabine concentrations,
ranging from 0 to 20 μM for 24 hrs. MtDNA was extracted and mtAP-sites were
quantitated using ARP reagent. As shown in Figure 6-8. A, increased drug concentrations
resulted in proportionally higher levels of mtAP-sites (r = 0.971). This suggests that
fludarabine targets mtDNA and that the induced damage is processed by the
mitochondrial repair pathway. However, when cells were treated with fludarabine and
methoxyamine (3 mM) detectable AP sites were reduced almost to the control levels due
to binding of MX. This suggests that MX is able to bind not only nuclear, but also
mitochondrial AP sites. The large extent of persistent fludarabine-induced nuclear and
mitochondrial DNA damage due to MX suggests that MX-AP sites are key DNA lesions
which potentiate the apoptotic death of fludarabine. Thus, apoptosis was assayed.
Exposure of cells to fludarabine alone (0- 20 μM) for 24 hrs resulted in a modest degree
of apoptosis (6 % increase over control values at 20 μM). However, combination of
fludarabine with MX for 24 hrs resulted in a 2-fold increase in apoptosis (14 % at 20 μM)
(Figure 6-8. B). Similar potentiation of apoptosis by MX was seen in a time course
analysis (data not shown). To further determine the role of mitochondria in apoptosis
mechanism, we measured treatment-mediated changes in mitochondrial membrane ΔΨm
using fluorescent mitochondrial probe JC-1. Time course response analysis of CLL
lymphocytes treated with 5 μM fludarabine revealed that the percentage of cells which
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lost their mitochondrial membrane integrity and, subsequently, their ability to accumulate
JC1 dye increased from 7 % at 24 hrs to 30 % at 72 hrs (Figure 6-8. C). When cells were
co-treated with MX the percentage of cells with damaged mitochondria increased to 29 %
at 24 hrs and to 42 % at 72 hrs, respectively. Moreover, the results were confirmed by
western blot analysis for mitochondrial related apoptotic proteins. As shown in Figure 66. D, combined treatment resulted in a very clear induction of pro-apoptotic protein Bax
at 24 hrs and lasted for at least 72 hrs. Since a key marker of mitochondrial apoptotic
cascade is the activation of caspase 9 by proteolytic cleavage, we examined the levels of
the cleaved fragment (Figure 6-8. D). Cleaved caspase 9 was observed at 48 hrs and 72
hrs after treatment with fludarabine alone or fludarabine plus MX. However, in
fludarabine plus MX treatments caspase 9 cleavage was ~2-fold greater than in cells
treated with fludarabine alone. Similar results were obtained for another marker of the
apoptotic cascade, the proteolytic cleavage of PARP by caspases (Figure 6-6. D). No
changes were observed in the expression levels of Bcl2, an anti-apoptotic molecule.
Together, these results demonstrate that MX potentiates fludarabine in vitro. Results also
demonstrate that fludarabine induced ara-AP sites in mitochondrial DNA and they
suggest that the mtDNA damage could play a significant role in mediating activation of
apoptosis and cell death following fludarabine treatments.
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Figure 6-8
Mitochondrial DNA damage and activation of mitochondrial-mediated cell death
A, The dose–dependent relationship between the numbers of mitochondrial ara-AP sites
and the concentrations of fludarabine. CLL cells were continuously treated with
fludarabine alone (0-20 µM) or fludarabine plus MX (3 mM). Mitochondrial DNA was
extracted and ara-AP sites were measured using aldehyde reactive probe reagent. (*,
p<0.05). B, Induction of apoptosis by the combined treatment fludarabine and
methoxyamine. CLL lymphocytes were continuously treated with fludarabine alone (5
μM) or fludarabine plus MX (3 mM), collected at 24 hrs and assayed for apoptosis by
Annexin V staining and flow cytometry analysis. C, Increased mitochondrial membrane
potential loss measured in cells treated with combined agents for 24 hrs. D, Aliquots of
the samples used in B were subjected to Western blot analysis with Bcl2, Bax, Cleaved
caspases 9, Cleaved PARP and tubulin specific antibodies. Control (lane 1), fludarabine
alone (lane 2,4,6) and fludarabine plus MX lanes (3,5.7), MX alone (lane 8).
Representative of three independent experiments.
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6.4.

Discussion

Base excision repair is a major repair pathway that corrects DNA modifications
arising either spontaneously or after attack by exogenous DNA damaging factors, such as
certain cancer therapies. An efficient BER can reverse the DNA damage caused by
therapeutic agents leading to development of resistance. However, BER therapeutic
implications have been evaluated by several targeted approaches, such as blocking of the
repair pathway by methoxyamine (MX) or PARP-inhibitors (48). In this study we
underlined the possibility of exploiting BER pathway in primary CLL lymphocytes as a
basis for targeted combinatory therapy involving standard therapeutic agent, fludarabine.
This conclusion is based on several lines of evidence. (i) The primary lymphocytes
isolated from CLL patients exhibited higher BER proteins expressions and increased BER
activity when compared to normal lymphocytes. (ii) BER involvement in response to
fludarabine-induced damage was confirmed by generation of ara-AP sites. (iii) Ara-AP
sites formed by fludarabine were bound by MX leading to induction of protein levels of
key BER proteins and resulted in DNA strand beaks and cell death. (iv) Mitochondrial
DNA was found to be a target of fludarabine and MX that triggers mitochondrial mediated
apoptosis following disruption of mitochondrial BER.
Fludarabine-induced cytotoxicity is enhanced when active BER pathway in primary
CLL is inhibited by MX.
BER is more active in CLL compared with normal lymphocytes. BER is an important
factor in cancer treatment based on several considerations: drug efficacy is influenced by
the efficiency of repair pathway, increased levels of DNA repair proteins have been
correlated with resistance to anticancer agents acting as DNA-damaging agents and
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understanding the repair pathway have made it potentially ‘druggable’ target for the
enhanced anti-tumor activity of DNA-damaging agents (48). Based on our previous
studies (Chapter 3, Chapter 4), two BER proteins have been shown to play an important
role in response to fludarabine induced damage: UDG and APE. When comparing the
basal levels of these proteins along with their activity on specific BER substrates, the
results showed a clear, significant difference: both proteins have higher expression levels
and activity in CLL cells, compared with normal lymphocytes. In contrast, the protein
expression pattern in CLL samples is similar with the ones measured in other human
cancer cells. Although more studies are needed, these findings suggest a possible
mechanism of resistance of CLL lymphocytes toward fludarabine and set the stage for
potential combinatory therapy to reduce the development of resistance to fludarabine.
Additionally, based on this difference between the normal and tumor primary cells,
targeting BER may be a selective approach to enhance fludarabine potency with lower
toxicity toward normal tissue. Furthermore, the intrinsic higher level of expression of
BER proteins may play a role in the limited sensitivity of CLL for fludarabine.
MX stabilizes ara-AP sites induced by fludarabine. Intermediates in BER, AP-sites are
formed as a consequence of the removal of modified bases by DNA glycosylases, the
first step in BER pathway. We have previously identified (Chapter 3 and Chapter 4) that
uracil DNA glycosylase plays a role in processing of incorporated fludarabine leading to
formation of ara-AP sites (21). In the present study, we report that fludarabine treatment
of lymphocytes from CLL samples resulted in a dose- and time- dependent formation of
ara-AP sites, suggesting that the repair pathway is involved in response of lymphocytes to
fludarabine-induced DNA damage. Also, our results confirmed that non-toxic doses of
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MX are sufficient for effective binding of the ara-AP sites formed by fludarabine. BER
involvement in response to MX plus fludarabine treatments of CLL was also confirmed
by increased expression levels of UDG and polymerase β.
MX-bound AP-sites generate double strand breaks and cell death. Formation of MXbound AP-sites following treatment with fludarabine and MX resulted in double strand
breaks and cell death. This increase in double stranded breaks can be explained by
previous data from our laboratory demonstrating that AP sites can act as topoisomerase II
poisons, trapping the protein into stabilized cleavable complexes (31). Indeed, formation
of MX-bound AP-sites was accompanied by higher expression levels of topo II in CLL
cells supporting the above mentioned scenario.
Fludarabine and MX treatment triggers mitochondrial mediated apoptotic cell
death in CLL cells. To determine the mechanism of apoptotic cell death, we focused on
mitochondrial involvement in this process. MtDNA is more prone to cytotoxic damage
due to several factors such as lack of protective histone, production of reactive oxygen
species and limited repair capacities (41,43). Recent studies showed that BER pathway is
the predominant repair pathway in mitochondria (42). Thus, we measured the formation
of ara-AP sites in mtDNA after exposure to fludarabine. Data have shown that
mitochondrial ara-AP sites formation is in dose dependent fashion and that MX binds
these ara-AP sites, thereby blocking the BER pathway in mitochondria. The level of
mtDNA damage eventually becomes severe, mitochondria lose their ability to maintain
the membrane potential and activate mitochondrial apoptotic death pathway.
These results suggest a possible synergistic approach for enhancing fludarabine
cancer therapy that involves disruption of base excision repair in CLL lymphocytes. This
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therapeutic strategy could improve both therapeutic index by decreasing the dose of
anticancer drugs and therapeutic efficacy for the treatment of hematological
malignancies.
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CHAPTER VII
SUMMARY AND FUTURE DIRECTIONS

The work presented here focused on investigating the involvement of BER
pathway in the response to fludarabine induced DNA damage and the possibility of
enhancing antineoplastic activity of fludarabine by inhibition of BER (e.g.
methoxyamine). Key findings of this research include:

(i) Uracil DNA glycosylase is the BER enzyme responsible for recognition and removal
of fludarabine incorporated into DNA strand, triggering activation of BER pathway
and subsequent formation of ara-AP sites.

(ii) By completion of BER, the cytotoxic potential of fludarabine is diminished,
suggesting a possible mechanism of resistance.
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(iii) MX, an inhibitor of BER, enhances fludarabine cytotoxicity through its ability to bind
to fludarabine-induced ara-AP sites; new MX-bound AP-sites formed are resistant to
BER action and the blockage of BER increases cell death in vitro and in human
xenografts.

(iv) Mitochondrial DNA is a target of fludarabine plus MX; inhibition of mtBER leads to
accumulation of mtDNA damage that will eventually result in mitochondrial
mediated apoptotic cell death.

(v) MX potentiates the antineoplastic activity of fludarabine in primary CLL
lymphocytes, setting the stage for the development a novel therapeutic strategy by
combining the inhibitor of BER (MX) with fludarabine.

The chart in next page outlines the connection between the main results presented
in this thesis, results which also set up the basis for future investigations.
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Figure 7-1. Conclusions
A. Fludarabine

B. Fludarabine plus MX
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Future efforts will be directed toward three main focus areas:
(i) Uracil DNA glycosylase and other BER glycosylases.
Investigations involving crystal structure of human UDG bound to DNA
containing F-ara-A should help elucidating the mechanism by which UDG recognizes
and removes fludarabine base from DNA helix and establishing the specific role of the
fluorine substitute in the biochemical mechanism of the enzymatic reaction.
Studies aimed to understand “if and how” the localization of incorporated
fludarabine (in-DNA-strand vs. at-3’-DNA-end) is important for UDG activity will be
carried out, starting with oligonucleotide substrates containing fludarabine at different
positions and in vitro tests.
(ii) Mitochondrial involvement in the apoptotic cell death.
Detection of early apoptotic events is of crucial importance. To understand more
precisely the sequential steps in fludarabine-induced apoptosis, we will continue the
studies presented in Chapter 5, where we have shown that not only nuclear DNA, but also
mtDNA is a target for fludarabine. Next question: Is the mitochondrial DNA damage
prevailing in signaling for apoptosis?
iii) Translating the preclinical data into clinical use.
As underlined in Chapter 6, preliminary studies using primary CLL cells have
shown promising results regarding the therapeutic potential of the combination
fludarabine plus MX. Thus, we will aim to include this combination into clinical
application. While the path toward implementing a new therapy is a very long and
complex endeavor, small but well coordinated steps and perseverance are some of the
necessary ingredients for success.
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